<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2010-05-03" updated="2020-01-02">
  <drugbank-id primary="true">DB06695</drugbank-id>
  <name>Dabigatran etexilate</name>
  <description>Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran][Label,A177463,A6970]. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated[A177463]. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary[A177463]. Dabigatran etexilate was approved by the FDA in 2010[L6022].</description>
  <cas-number>211915-06-9</cas-number>
  <unii>2E18WX195X</unii>
  <average-mass>627.7332</average-mass>
  <monoisotopic-mass>627.316917457</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A6977</ref-id>
        <pubmed-id>17764540</pubmed-id>
        <citation>Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85.</citation>
      </article>
      <article>
        <ref-id>A6978</ref-id>
        <pubmed-id>17869635</pubmed-id>
        <citation>Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR: Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56.</citation>
      </article>
      <article>
        <ref-id>A6979</ref-id>
        <pubmed-id>23292752</pubmed-id>
        <citation>Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9.</citation>
      </article>
      <article>
        <ref-id>A17924</ref-id>
        <pubmed-id>20551237</pubmed-id>
        <citation>Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15.</citation>
      </article>
      <article>
        <ref-id>A177463</ref-id>
        <pubmed-id>23408233</pubmed-id>
        <citation>van Ryn J, Goss A, Hauel N, Wienen W, Priepke H, Nar H, Clemens A: The discovery of dabigatran etexilate. Front Pharmacol. 2013 Feb 12;4:12. doi: 10.3389/fphar.2013.00012. eCollection 2013.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L6022</ref-id>
        <title>FDA Drug Approval Package for Dabigatran Etexilate</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512orig1s000toc.cfm</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F4423</ref-id>
        <title>Apotex Inc. Product Monograph: Dabigatran Etexilate</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/004/423/original/Apotex_Inc_Product_Monograph_Dabigatran_Etexilate.PDF?1555955264</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference>Christian Filser, Wolfgang Dersch, Rainer Hamm, Arndt Hausherr, Gunter Koch, Ulrich Scholz, Georg Zerban, "METHOD FOR PRODUCING AN INTERMEDIATE PRODUCT OF DABIGATRAN ETEXILATE." U.S. Patent US20110118471, issued May 19, 2011.</synthesis-reference>
  <indication>Dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials)[A177463,A6978,A6977]. In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial)[Label,A177463].</indication>
  <pharmacodynamics>Dabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results in a prolongation of aPTT (partial thromboplastin time), ECT (Ecarin clotting time), and TT (thrombin time)[Label,A177463,A6970].</pharmacodynamics>
  <mechanism-of-action>Dabigatran is hydrolysed to the active dabigatran by an esterase which induces hydrolysis[Label,A17924]. Dabigatran and it's glucuronidated metabolites all share equal pharmacological activity[Label,A17924]. Dabigatran and its metabolites inhibit thrombin, a serine protease[Label,A17924,A6970]. This inhibition prevents the thrombin mediated conversion of fibrinogen to fibrin, an early step in the coagulation cascade[Label,A17924]. With reduced conversion of fibrinogen to fibrin, clotting time increases.</mechanism-of-action>
  <toxicity>No human studies involving pregnancy, labor and delivery, nursing, or pediatrics[Label]. Geriatric patients are at higher risk of adverse effects than younger patients but the risk to benefit ratio is generally still favourable for older patients[Label]. Patients with a creatinine clearance of 15-30mL/min should have their doses of dabigatran etexilate reduced, and no data is available for patients with a creatinine clearance below 15mL/min[Label].&#13;
&#13;
In animal studies, dabigatran increases the rates of dead offspring and causes uterine and vaginal bleeding close to birth[Label]. Dabigatran may or may not be excreted in breast milk so the risk and benefit of stopping the drug or stopping breast feeding must be considered[Label].</toxicity>
  <metabolism>Dabigatran etexilate is metabolised by esterases, microsomal carboxylesterases, and uridine 5'-diphospho-glucuronosyltransferases(UGTs)[Label,A17924]. Dabigatran etexilate undergoes hydrolysis to create the active dabigatran which is then glucuronidated by UGTs to 1-O, 2-O, 3-O, or 4-O-acylglucuronide[Label,A17924,A6970].</metabolism>
  <absorption>Oral dabigatran is 3-7% bioavailable, reaching a maximum concentration 1 hour after administration in fasted subjects[Label]. When taken with a meal that is high in fat, the time to maximum concentration increases to 2 hours, though this does not affect dosing[Label,A177463]. Dabigatran etexilate's bioavailability increases to 75% when taken without the capsule shell and so patients should not chew or crush the capsules[Label].</absorption>
  <half-life>12 to 17 hours[Label,A177463].</half-life>
  <protein-binding>Dabigatran is approximately 35% protein plasma bound[Label,A177463].</protein-binding>
  <route-of-elimination>7% of the dose is recovered in urine and 86% is recovered in the feces[Label].</route-of-elimination>
  <volume-of-distribution>50-70L[Label].</volume-of-distribution>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).</description>
    <direct-parent>Benzimidazoles</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Benzimidazoles</class>
    <subclass/>
    <alternative-parent>Amino acids and derivatives</alternative-parent>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Carboxamidines</alternative-parent>
    <alternative-parent>Carboximidamides</alternative-parent>
    <alternative-parent>Carboxylic acid esters</alternative-parent>
    <alternative-parent>Heteroaromatic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Imidolactams</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>N-substituted imidazoles</alternative-parent>
    <alternative-parent>Organic carbonic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Phenylalkylamines</alternative-parent>
    <alternative-parent>Propargyl-type 1,3-dipolar organic compounds</alternative-parent>
    <alternative-parent>Pyridines and derivatives</alternative-parent>
    <alternative-parent>Secondary alkylarylamines</alternative-parent>
    <alternative-parent>Tertiary carboxylic acid amides</alternative-parent>
    <substituent>Amidine</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Aralkylamine</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Azole</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Benzimidazole</substituent>
    <substituent>Carbonic acid derivative</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboximidamide</substituent>
    <substituent>Carboxylic acid amidine</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Carboxylic acid ester</substituent>
    <substituent>Heteroaromatic compound</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Imidazole</substituent>
    <substituent>Imidolactam</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-substituted imidazole</substituent>
    <substituent>Organic 1,3-dipolar compound</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenylalkylamine</substituent>
    <substituent>Propargyl-type 1,3-dipolar organic compound</substituent>
    <substituent>Pyridine</substituent>
    <substituent>Secondary aliphatic/aromatic amine</substituent>
    <substituent>Secondary amine</substituent>
    <substituent>Tertiary carboxylic acid amide</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000035</drugbank-id>
      <name>Dabigatran etexilate mesilate</name>
      <unii>SC7NUW5IIT</unii>
      <cas-number>872728-81-9</cas-number>
      <inchikey>XETBXHPXHHOLOE-UHFFFAOYSA-N</inchikey>
      <average-mass>723.839</average-mass>
      <monoisotopic-mass>723.305032141</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn/usan">Dabigatran etexilate</synonym>
  </synonyms>
  <products>
    <product>
      <name>Apo-dabigatran</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02468913</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-dabigatran</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02468905</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-dabigatran</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02468891</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-899</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/015</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>110 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/010</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/005</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>110 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4480</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/019</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/014</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>110 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/009</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02358808</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/004</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3617</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-11-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>110 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/018</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>110 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/013</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/008</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>110 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02312441</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>110 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/003</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-11-08</started-marketing-on>
      <ended-marketing-on>2010-10-25</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0149</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/017</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/012</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/007</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>110 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim (Canada) Ltd Ltee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02312433</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-07-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/002</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0360</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-6276</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-10-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/016</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/011</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/006</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>110 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-8242</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000829</ema-product-code>
      <ema-ma-number>EU/1/08/442/001</ema-ma-number>
      <started-marketing-on>2008-03-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Pradaxa</name>
      <labeller>Boehringer Ingelheim</labeller>
      <ndc-id/>
      <ndc-product-code>0597-0355</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-08-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA022512</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Teva-dabigatran</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02463458</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-dabigatran</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02463466</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Pradax</name>
      <company>Boehringer Ingelheim</company>
    </international-brand>
    <international-brand>
      <name>Rendix</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Pradaxa</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Teva-dabigatran</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Teva-dabigatran</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-dabigatran</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-dabigatran</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
    <mixture>
      <name>Apo-dabigatran</name>
      <ingredients>Dabigatran etexilate</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anticoagulants</category>
      <mesh-id>D000925</mesh-id>
    </category>
    <category>
      <category>Antithrombins</category>
      <mesh-id>D000991</mesh-id>
    </category>
    <category>
      <category>Benzimidazoles</category>
      <mesh-id>D001562</mesh-id>
    </category>
    <category>
      <category>Blood and Blood Forming Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Drugs that are Mainly Renally Excreted</category>
      <mesh-id/>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Hematologic Agents</category>
      <mesh-id>D006401</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Narrow Therapeutic Index Drugs</category>
      <mesh-id/>
    </category>
    <category>
      <category>P-glycoprotein substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>P-glycoprotein substrates with narrow therapeutic index</category>
      <mesh-id/>
    </category>
    <category>
      <category>Protease Inhibitors</category>
      <mesh-id>D011480</mesh-id>
    </category>
    <category>
      <category>Pyridines</category>
      <mesh-id>D011725</mesh-id>
    </category>
    <category>
      <category>Serine Protease Inhibitors</category>
      <mesh-id>D015842</mesh-id>
    </category>
    <category>
      <category>UGT1A9 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>UGT1A9 substrates with narrow therapeutic index</category>
      <mesh-id/>
    </category>
    <category>
      <category>UGT2B7 substrates</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>110 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>110 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>150 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>150 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>75 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>75 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="B01AE07">
      <level code="B01AE">Direct thrombin inhibitors</level>
      <level code="B01A">ANTITHROMBOTIC AGENTS</level>
      <level code="B01">ANTITHROMBOTIC AGENTS</level>
      <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>20:12.04.12</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06695.pdf?1555946177</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB06695.pdf?1367194088</msds>
  <patents>
    <patent>
      <number>9034822</number>
      <country>United States</country>
      <approved>2015-05-19</approved>
      <expires>2031-01-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6087380</number>
      <country>United States</country>
      <approved>2000-07-11</approved>
      <expires>2018-02-18</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7932273</number>
      <country>United States</country>
      <approved>2011-04-26</approved>
      <expires>2025-09-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7866474</number>
      <country>United States</country>
      <approved>2011-01-11</approved>
      <expires>2027-08-31</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9925174</number>
      <country>United States</country>
      <approved>2018-03-27</approved>
      <expires>2023-06-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>St. John's Wort</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>Apixaban may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Drotrecogin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Pentosan polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Desmoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Defibrotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Beraprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Fibrinolysin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Prasugrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Semuloparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Cangrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Astaxanthin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Triflusal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Ditazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Vorapaxar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Potassium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Zinc citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Antithrombin Alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Letaxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Darexaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Betrixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Monteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Brinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Melagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Edetate calcium disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>Dabigatran etexilate may increase the anticoagulant activities of Dabigatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The risk or severity of gastrointestinal bleeding can be increased when Dabigatran etexilate is combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01586</drugbank-id>
      <name>Ursodeoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Ursodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02123</drugbank-id>
      <name>Glycochenodeoxycholic Acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Glycochenodeoxycholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02691</drugbank-id>
      <name>Glycocholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Glycocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03619</drugbank-id>
      <name>Deoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Deoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05990</drugbank-id>
      <name>Obeticholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Obeticholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06777</drugbank-id>
      <name>Chenodeoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Chenodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08833</drugbank-id>
      <name>Taurochenodeoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Taurochenodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08834</drugbank-id>
      <name>Tauroursodeoxycholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Tauroursodeoxycholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08857</drugbank-id>
      <name>Bamet-UD2</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Bamet-UD2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Dehydrocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11789</drugbank-id>
      <name>Hyodeoxycholic Acid</name>
      <description>The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Hyodeoxycholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Dabigatran etexilate is combined with Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06206</drugbank-id>
      <name>Sugammadex</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Dabigatran etexilate is combined with Sugammadex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09070</drugbank-id>
      <name>Tibolone</name>
      <description>Tibolone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00163</drugbank-id>
      <name>Vitamin E</name>
      <description>Vitamin E may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>Nizatidine can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>Famotidine can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>Methantheline can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>Aluminium can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>Magnesium oxide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01390</drugbank-id>
      <name>Sodium bicarbonate</name>
      <description>Sodium bicarbonate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>Aluminum hydroxide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>Calcium carbonate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08805</drugbank-id>
      <name>Metiamide</name>
      <description>Metiamide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08806</drugbank-id>
      <name>Roxatidine acetate</name>
      <description>Roxatidine acetate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>Magaldrate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>Magnesium hydroxide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>Magnesium trisilicate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>Magnesium carbonate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12770</drugbank-id>
      <name>Lafutidine</name>
      <description>Lafutidine can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12884</drugbank-id>
      <name>Lavoltidine</name>
      <description>Lavoltidine can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>Bismuth subnitrate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>Magnesium silicate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>Aluminium acetoacetate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>Hydrotalcite can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>Magnesium peroxide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>Almasilate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>Aluminium glycinate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>Aloglutamol can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13760</drugbank-id>
      <name>Niperotidine</name>
      <description>Niperotidine can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>Calcium silicate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>Aluminium phosphate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>Rabeprazole can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>Dexlansoprazole can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>Dexrabeprazole can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15246</drugbank-id>
      <name>Salvianolic acid A</name>
      <description>Salvianolic acid A can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01381</drugbank-id>
      <name>Ginkgo biloba</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be increased when used in combination with Ginkgo biloba.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The risk or severity of bleeding can be increased when Ifosfamide is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>Ticagrelor may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00583</drugbank-id>
      <name>Levocarnitine</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be increased when used in combination with Levocarnitine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>Diethylstilbestrol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00269</drugbank-id>
      <name>Chlorotrianisene</name>
      <description>Chlorotrianisene may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>Conjugated estrogens may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>Estradiol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>Ethinylestradiol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>Mestranol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>Estrone sulfate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04575</drugbank-id>
      <name>Quinestrol</name>
      <description>Quinestrol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07931</drugbank-id>
      <name>Hexestrol</name>
      <description>Hexestrol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09317</drugbank-id>
      <name>Synthetic Conjugated Estrogens, A</name>
      <description>Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09318</drugbank-id>
      <name>Synthetic Conjugated Estrogens, B</name>
      <description>Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09369</drugbank-id>
      <name>Polyestradiol phosphate</name>
      <description>Polyestradiol phosphate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09381</drugbank-id>
      <name>Esterified estrogens</name>
      <description>Esterified estrogens may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11478</drugbank-id>
      <name>Zeranol</name>
      <description>Zeranol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11674</drugbank-id>
      <name>Equol</name>
      <description>Equol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12487</drugbank-id>
      <name>Promestriene</name>
      <description>Promestriene may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13143</drugbank-id>
      <name>Methallenestril</name>
      <description>Methallenestril may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13386</drugbank-id>
      <name>Epimestrol</name>
      <description>Epimestrol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13418</drugbank-id>
      <name>Moxestrol</name>
      <description>Moxestrol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>Estradiol acetate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>Estradiol benzoate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>Estradiol cypionate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>Estradiol valerate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15334</drugbank-id>
      <name>Biochanin A</name>
      <description>Biochanin A may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15335</drugbank-id>
      <name>Formononetin</name>
      <description>Formononetin may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09211</drugbank-id>
      <name>Limaprost</name>
      <description>The risk or severity of adverse effects can be increased when Limaprost is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Olsalazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Metamizole is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Felbinac is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Betulinic Acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Flunoxaprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Feprazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Bendazac is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pranoprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04865</drugbank-id>
      <name>Omacetaxine mepesuccinate</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Omacetaxine mepesuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11133</drugbank-id>
      <name>Omega-3 fatty acids</name>
      <description>Omega-3 fatty acids may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00081</drugbank-id>
      <name>Tositumomab</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Dabigatran etexilate is combined with Tositumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00048</drugbank-id>
      <name>Collagenase clostridium histolyticum</name>
      <description>The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Collagenase clostridium histolyticum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>Carbimazole may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>Propylthiouracil may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03374</drugbank-id>
      <name>3,5-Diiodotyrosine</name>
      <description>3,5-Diiodotyrosine may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>Potassium Iodide may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07637</drugbank-id>
      <name>Dibromotyrosine</name>
      <description>Dibromotyrosine may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13644</drugbank-id>
      <name>Methylthiouracil</name>
      <description>Methylthiouracil may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13804</drugbank-id>
      <name>Benzylthiouracil</name>
      <description>Benzylthiouracil may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04066</drugbank-id>
      <name>para-Coumaric Acid</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with para-Coumaric Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04682</drugbank-id>
      <name>Octylphenoxy polyethoxyethanol</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Octylphenoxy polyethoxyethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05830</drugbank-id>
      <name>Trestolone</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Trestolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06266</drugbank-id>
      <name>Lonidamine</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Lonidamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08867</drugbank-id>
      <name>Ulipristal</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Ulipristal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09401</drugbank-id>
      <name>Isosorbide</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Isosorbide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11507</drugbank-id>
      <name>Cloprostenol</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Cloprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12025</drugbank-id>
      <name>Triptolide</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Triptolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13044</drugbank-id>
      <name>Gossypol</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Gossypol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13310</drugbank-id>
      <name>Ormeloxifene</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Ormeloxifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>Etonogestrel may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>Desogestrel may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>Levonorgestrel may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00378</drugbank-id>
      <name>Dydrogesterone</name>
      <description>Dydrogesterone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>Ethynodiol diacetate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>Norgestimate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>Drospirenone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01431</drugbank-id>
      <name>Allylestrenol</name>
      <description>Allylestrenol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>Cyproterone acetate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06713</drugbank-id>
      <name>Norelgestromin</name>
      <description>Norelgestromin may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>Gestodene may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>Hydroxyprogesterone caproate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>Dienogest may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09124</drugbank-id>
      <name>Medrogestone</name>
      <description>Medrogestone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09371</drugbank-id>
      <name>Norethynodrel</name>
      <description>Norethynodrel may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09389</drugbank-id>
      <name>Norgestrel</name>
      <description>Norgestrel may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11372</drugbank-id>
      <name>Altrenogest</name>
      <description>Altrenogest may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11619</drugbank-id>
      <name>Gestrinone</name>
      <description>Gestrinone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11636</drugbank-id>
      <name>Nomegestrol</name>
      <description>Nomegestrol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12474</drugbank-id>
      <name>Lynestrenol</name>
      <description>Lynestrenol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13230</drugbank-id>
      <name>Gestonorone</name>
      <description>Gestonorone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13528</drugbank-id>
      <name>Chlormadinone</name>
      <description>Chlormadinone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13533</drugbank-id>
      <name>Methylestrenolone</name>
      <description>Methylestrenolone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13563</drugbank-id>
      <name>Norgestrienone</name>
      <description>Norgestrienone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13602</drugbank-id>
      <name>Promegestone</name>
      <description>Promegestone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13685</drugbank-id>
      <name>Quingestanol</name>
      <description>Quingestanol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13857</drugbank-id>
      <name>Demegestone</name>
      <description>Demegestone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13866</drugbank-id>
      <name>Etynodiol</name>
      <description>Etynodiol may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13981</drugbank-id>
      <name>Nomegestrol acetate</name>
      <description>Nomegestrol acetate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14570</drugbank-id>
      <name>Hydroxyprogesterone</name>
      <description>Hydroxyprogesterone may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14678</drugbank-id>
      <name>Norethindrone enanthate</name>
      <description>Norethindrone enanthate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14679</drugbank-id>
      <name>Quingestanol acetate</name>
      <description>Quingestanol acetate may decrease the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic acid</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>Dersalazine</name>
      <description>The risk or severity of bleeding can be increased when Dersalazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06807</drugbank-id>
      <name>Phenyl aminosalicylate</name>
      <description>The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09543</drugbank-id>
      <name>Methyl salicylate</name>
      <description>The risk or severity of bleeding can be increased when Methyl salicylate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11079</drugbank-id>
      <name>Trolamine salicylate</name>
      <description>The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13509</drugbank-id>
      <name>Aloxiprin</name>
      <description>The risk or severity of bleeding can be increased when Aloxiprin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>The risk or severity of bleeding can be increased when Choline salicylate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14026</drugbank-id>
      <name>Thiosalicylic acid</name>
      <description>The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of bleeding can be increased when Treprostinil is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00078</drugbank-id>
      <name>Ibritumomab tiuxetan</name>
      <description>The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Ibritumomab tiuxetan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>Eptifibatide may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>Ticlopidine may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>Clopidogrel may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>Tirofiban may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>Pentoxifylline may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>Sulfinpyrazone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>Cilostazol may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>Ridogrel may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>Sevoflurane may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>Resveratrol may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>Nimesulide may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>Ibudilast may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>Andrographolide may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>Caplacizumab may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>Tranilast may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>Icosapent ethyl may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>Trapidil may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>Naftopidil may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>Sarpogrelate may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12321</drugbank-id>
      <name>Ifetroban</name>
      <description>Ifetroban may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>Ketanserin may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>Indobufen may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>Butylphthalide may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12771</drugbank-id>
      <name>Hydroxytyrosol</name>
      <description>Hydroxytyrosol may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>Ramatroban may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13327</drugbank-id>
      <name>Picotamide</name>
      <description>Picotamide may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13367</drugbank-id>
      <name>Cloricromen</name>
      <description>Cloricromen may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>Linsidomine may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>Buflomedil may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13929</drugbank-id>
      <name>Relcovaptan</name>
      <description>Relcovaptan may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03404</drugbank-id>
      <name>Hemin</name>
      <description>Hemin may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Rilpivirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Acemetacin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>Testosterone propionate may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01481</drugbank-id>
      <name>1-Testosterone</name>
      <description>1-Testosterone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01485</drugbank-id>
      <name>4-Hydroxytestosterone</name>
      <description>4-Hydroxytestosterone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01510</drugbank-id>
      <name>Dehydrochloromethyltestosterone</name>
      <description>Dehydrochloromethyltestosterone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01541</drugbank-id>
      <name>Boldenone</name>
      <description>Boldenone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01543</drugbank-id>
      <name>18-methyl-19-nortestosterone</name>
      <description>18-methyl-19-nortestosterone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01564</drugbank-id>
      <name>Calusterone</name>
      <description>Calusterone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01569</drugbank-id>
      <name>Formebolone</name>
      <description>Formebolone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01572</drugbank-id>
      <name>Methyl-1-testosterone</name>
      <description>Methyl-1-testosterone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02901</drugbank-id>
      <name>Stanolone</name>
      <description>Stanolone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07447</drugbank-id>
      <name>5beta-dihydrotestosterone</name>
      <description>5beta-dihydrotestosterone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08619</drugbank-id>
      <name>Testosterone succinate</name>
      <description>Testosterone succinate may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11429</drugbank-id>
      <name>Mibolerone</name>
      <description>Mibolerone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13947</drugbank-id>
      <name>Testosterone enantate benzilic acid hydrazone</name>
      <description>Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13951</drugbank-id>
      <name>Stanolone acetate</name>
      <description>Stanolone acetate may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13958</drugbank-id>
      <name>Trestolone acetate</name>
      <description>Trestolone acetate may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14093</drugbank-id>
      <name>(1,2,6,7-3H)Testosterone</name>
      <description>(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14655</drugbank-id>
      <name>Drostanolone propionate</name>
      <description>Drostanolone propionate may increase the anticoagulant activities of Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11051</drugbank-id>
      <name>Azficel-T</name>
      <description>The risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Azficel-T.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09568</drugbank-id>
      <name>Omega-3-carboxylic acids</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be increased when used in combination with Omega-3-carboxylic acids.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00025</drugbank-id>
      <name>Antihemophilic factor, human recombinant</name>
      <description>The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00036</drugbank-id>
      <name>Coagulation factor VIIa Recombinant Human</name>
      <description>The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00100</drugbank-id>
      <name>Coagulation Factor IX (Recombinant)</name>
      <description>The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00258</drugbank-id>
      <name>Calcium acetate</name>
      <description>The therapeutic efficacy of Calcium acetate can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01164</drugbank-id>
      <name>Calcium chloride</name>
      <description>The therapeutic efficacy of Calcium Chloride can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01373</drugbank-id>
      <name>Calcium</name>
      <description>The therapeutic efficacy of Calcium can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01783</drugbank-id>
      <name>Pantothenic acid</name>
      <description>The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01942</drugbank-id>
      <name>Formic acid</name>
      <description>The therapeutic efficacy of Formic acid can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09109</drugbank-id>
      <name>Turoctocog alfa</name>
      <description>The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09222</drugbank-id>
      <name>Fibrinogen human</name>
      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09310</drugbank-id>
      <name>Catridecacog</name>
      <description>The therapeutic efficacy of Catridecacog can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09329</drugbank-id>
      <name>Antihemophilic Factor (Recombinant), PEGylated</name>
      <description>The therapeutic efficacy of Antihemophilic Factor (Recombinant), PEGylated can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11093</drugbank-id>
      <name>Calcium Citrate</name>
      <description>The therapeutic efficacy of Calcium Citrate can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11126</drugbank-id>
      <name>Calcium gluconate</name>
      <description>The therapeutic efficacy of Calcium gluconate can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11168</drugbank-id>
      <name>Calcium threonate</name>
      <description>The therapeutic efficacy of Calcium threonate can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11311</drugbank-id>
      <name>Prothrombin</name>
      <description>The therapeutic efficacy of Prothrombin can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11330</drugbank-id>
      <name>Factor IX Complex (Human)</name>
      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11348</drugbank-id>
      <name>Calcium Phosphate</name>
      <description>The therapeutic efficacy of Calcium Phosphate can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11606</drugbank-id>
      <name>Susoctocog alfa</name>
      <description>The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11608</drugbank-id>
      <name>Eftrenonacog alfa</name>
      <description>The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11668</drugbank-id>
      <name>Rusalatide acetate</name>
      <description>The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12409</drugbank-id>
      <name>Vatreptacog alfa</name>
      <description>The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12909</drugbank-id>
      <name>Factor XIII (human)</name>
      <description>The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13133</drugbank-id>
      <name>Von Willebrand Factor Human</name>
      <description>The therapeutic efficacy of Von Willebrand Factor Human can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13148</drugbank-id>
      <name>Coagulation factor X human</name>
      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13150</drugbank-id>
      <name>Coagulation factor VII human</name>
      <description>The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13151</drugbank-id>
      <name>Anti-inhibitor coagulant complex</name>
      <description>The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13152</drugbank-id>
      <name>Coagulation Factor IX Human</name>
      <description>The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13192</drugbank-id>
      <name>Antihemophilic factor human</name>
      <description>The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13197</drugbank-id>
      <name>Kallidinogenase</name>
      <description>The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13201</drugbank-id>
      <name>Trenonacog alfa</name>
      <description>The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13884</drugbank-id>
      <name>Albutrepenonacog alfa</name>
      <description>The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13923</drugbank-id>
      <name>Emicizumab</name>
      <description>The therapeutic efficacy of Emicizumab can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13933</drugbank-id>
      <name>Nonacog beta pegol</name>
      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13999</drugbank-id>
      <name>Moroctocog alfa</name>
      <description>The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14473</drugbank-id>
      <name>Beroctocog alfa</name>
      <description>The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14562</drugbank-id>
      <name>Andexanet alfa</name>
      <description>The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14577</drugbank-id>
      <name>Calcium cation</name>
      <description>The therapeutic efficacy of Calcium cation can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14700</drugbank-id>
      <name>Damoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14738</drugbank-id>
      <name>Turoctocog alfa pegol</name>
      <description>The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The risk or severity of hemorrhage can be increased when Seproxetine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The risk or severity of hemorrhage can be increased when Indalpine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The risk or severity of hemorrhage can be increased when Ritanserin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The risk or severity of hemorrhage can be increased when Alaproclate is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>The risk or severity of hemorrhage can be increased when Sibutramine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The risk or severity of hemorrhage can be increased when Milnacipran is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00229</drugbank-id>
      <name>Cefotiam</name>
      <description>Cefotiam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00267</drugbank-id>
      <name>Cefmenoxime</name>
      <description>Cefmenoxime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00274</drugbank-id>
      <name>Cefmetazole</name>
      <description>Cefmetazole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00282</drugbank-id>
      <name>Pamidronic acid</name>
      <description>Pamidronic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00369</drugbank-id>
      <name>Cidofovir</name>
      <description>Cidofovir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>Triamterene may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00430</drugbank-id>
      <name>Cefpiramide</name>
      <description>Cefpiramide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00438</drugbank-id>
      <name>Ceftazidime</name>
      <description>Ceftazidime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00447</drugbank-id>
      <name>Loracarbef</name>
      <description>Loracarbef may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00452</drugbank-id>
      <name>Framycetin</name>
      <description>Framycetin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00456</drugbank-id>
      <name>Cefalotin</name>
      <description>Cefalotin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00479</drugbank-id>
      <name>Amikacin</name>
      <description>Amikacin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00493</drugbank-id>
      <name>Cefotaxime</name>
      <description>Cefotaxime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>Foscarnet may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>Cephalexin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00577</drugbank-id>
      <name>Valaciclovir</name>
      <description>Valaciclovir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00626</drugbank-id>
      <name>Bacitracin</name>
      <description>Bacitracin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>Amphotericin B may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00684</drugbank-id>
      <name>Tobramycin</name>
      <description>Tobramycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00689</drugbank-id>
      <name>Cephaloglycin</name>
      <description>Cephaloglycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00718</drugbank-id>
      <name>Adefovir dipivoxil</name>
      <description>Adefovir dipivoxil may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Pentamidine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>Mannitol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>Acyclovir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00798</drugbank-id>
      <name>Gentamicin</name>
      <description>Gentamicin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00833</drugbank-id>
      <name>Cefaclor</name>
      <description>Cefaclor may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>Etacrynic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00923</drugbank-id>
      <name>Ceforanide</name>
      <description>Ceforanide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00955</drugbank-id>
      <name>Netilmicin</name>
      <description>Netilmicin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00958</drugbank-id>
      <name>Carboplatin</name>
      <description>Carboplatin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00994</drugbank-id>
      <name>Neomycin</name>
      <description>Neomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>Hydrochlorothiazide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01066</drugbank-id>
      <name>Cefditoren</name>
      <description>Cefditoren may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01082</drugbank-id>
      <name>Streptomycin</name>
      <description>Streptomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01111</drugbank-id>
      <name>Colistimethate</name>
      <description>Colistimethate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01112</drugbank-id>
      <name>Cefuroxime</name>
      <description>Cefuroxime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01139</drugbank-id>
      <name>Cefapirin</name>
      <description>Cefapirin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01140</drugbank-id>
      <name>Cefadroxil</name>
      <description>Cefadroxil may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01150</drugbank-id>
      <name>Cefprozil</name>
      <description>Cefprozil may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01172</drugbank-id>
      <name>Kanamycin</name>
      <description>Kanamycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01326</drugbank-id>
      <name>Cefamandole</name>
      <description>Cefamandole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01327</drugbank-id>
      <name>Cefazolin</name>
      <description>Cefazolin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01328</drugbank-id>
      <name>Cefonicid</name>
      <description>Cefonicid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01330</drugbank-id>
      <name>Cefotetan</name>
      <description>Cefotetan may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01331</drugbank-id>
      <name>Cefoxitin</name>
      <description>Cefoxitin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01332</drugbank-id>
      <name>Ceftizoxime</name>
      <description>Ceftizoxime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>Cefradine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01413</drugbank-id>
      <name>Cefepime</name>
      <description>Cefepime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01414</drugbank-id>
      <name>Cefacetrile</name>
      <description>Cefacetrile may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01415</drugbank-id>
      <name>Ceftibuten</name>
      <description>Ceftibuten may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01416</drugbank-id>
      <name>Cefpodoxime</name>
      <description>Cefpodoxime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01421</drugbank-id>
      <name>Paromomycin</name>
      <description>Paromomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02247</drugbank-id>
      <name>Hydrolyzed Cephalothin</name>
      <description>Hydrolyzed Cephalothin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03450</drugbank-id>
      <name>Cephalothin Group</name>
      <description>Cephalothin Group may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03615</drugbank-id>
      <name>Ribostamycin</name>
      <description>Ribostamycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04263</drugbank-id>
      <name>Geneticin</name>
      <description>Geneticin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04570</drugbank-id>
      <name>Latamoxef</name>
      <description>Latamoxef may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04626</drugbank-id>
      <name>Apramycin</name>
      <description>Apramycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04729</drugbank-id>
      <name>Gentamicin C1a</name>
      <description>Gentamicin C1a may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04808</drugbank-id>
      <name>Neamine</name>
      <description>Neamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04918</drugbank-id>
      <name>Ceftobiprole</name>
      <description>Ceftobiprole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06590</drugbank-id>
      <name>Ceftaroline fosamil</name>
      <description>Ceftaroline fosamil may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06696</drugbank-id>
      <name>Arbekacin</name>
      <description>Arbekacin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08437</drugbank-id>
      <name>Puromycin</name>
      <description>Puromycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09008</drugbank-id>
      <name>Cefaloridine</name>
      <description>Cefaloridine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09062</drugbank-id>
      <name>Cefminox</name>
      <description>Cefminox may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>Dexibuprofen may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09299</drugbank-id>
      <name>Tenofovir alafenamide</name>
      <description>Tenofovir alafenamide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11367</drugbank-id>
      <name>Cefroxadine</name>
      <description>Cefroxadine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11512</drugbank-id>
      <name>Dihydrostreptomycin</name>
      <description>Dihydrostreptomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11520</drugbank-id>
      <name>Hygromycin B</name>
      <description>Hygromycin B may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11935</drugbank-id>
      <name>Flomoxef</name>
      <description>Flomoxef may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12151</drugbank-id>
      <name>Brincidofovir</name>
      <description>Brincidofovir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12604</drugbank-id>
      <name>Sisomicin</name>
      <description>Sisomicin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13266</drugbank-id>
      <name>Cefatrizine</name>
      <description>Cefatrizine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13270</drugbank-id>
      <name>Dibekacin</name>
      <description>Dibekacin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13274</drugbank-id>
      <name>Micronomicin</name>
      <description>Micronomicin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13461</drugbank-id>
      <name>Cefcapene</name>
      <description>Cefcapene may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13470</drugbank-id>
      <name>Cefodizime</name>
      <description>Cefodizime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13499</drugbank-id>
      <name>Cefsulodin</name>
      <description>Cefsulodin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13504</drugbank-id>
      <name>Cefetamet</name>
      <description>Cefetamet may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13540</drugbank-id>
      <name>Isepamicin</name>
      <description>Isepamicin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13638</drugbank-id>
      <name>Cefbuperazone</name>
      <description>Cefbuperazone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13667</drugbank-id>
      <name>Cefozopran</name>
      <description>Cefozopran may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13673</drugbank-id>
      <name>Bekanamycin</name>
      <description>Bekanamycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13682</drugbank-id>
      <name>Cefpirome</name>
      <description>Cefpirome may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13778</drugbank-id>
      <name>Cefazedone</name>
      <description>Cefazedone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13821</drugbank-id>
      <name>Ceftezole</name>
      <description>Ceftezole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13868</drugbank-id>
      <name>Adefovir</name>
      <description>Adefovir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>Inotersen may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01438</drugbank-id>
      <name>Phenazopyridine</name>
      <description>Phenazopyridine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>Givosiran may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>Leuprolide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>Goserelin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>Salmon Calcitonin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>Desmopressin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>Aldesleukin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00080</drugbank-id>
      <name>Daptomycin</name>
      <description>Daptomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00115</drugbank-id>
      <name>Cyanocobalamin</name>
      <description>Cyanocobalamin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00158</drugbank-id>
      <name>Folic acid</name>
      <description>Folic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00165</drugbank-id>
      <name>Pyridoxine</name>
      <description>Pyridoxine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>Baclofen may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>Cevimeline may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>Lorazepam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00190</drugbank-id>
      <name>Carbidopa</name>
      <description>Carbidopa may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>Tramadol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00198</drugbank-id>
      <name>Oseltamivir</name>
      <description>Oseltamivir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00200</drugbank-id>
      <name>Hydroxocobalamin</name>
      <description>Hydroxocobalamin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00225</drugbank-id>
      <name>Gadodiamide</name>
      <description>Gadodiamide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>Pregabalin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>Temazepam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>Milrinone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>Butabarbital may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>Benzatropine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>Carmustine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00271</drugbank-id>
      <name>Diatrizoate</name>
      <description>Diatrizoate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Disopyramide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>Acarbose may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>Atomoxetine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00290</drugbank-id>
      <name>Bleomycin</name>
      <description>Bleomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>Etomidate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>Ropivacaine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00303</drugbank-id>
      <name>Ertapenem</name>
      <description>Ertapenem may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>Ibutilide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>Pentobarbital may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00319</drugbank-id>
      <name>Piperacillin</name>
      <description>Piperacillin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00322</drugbank-id>
      <name>Floxuridine</name>
      <description>Floxuridine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>Tolcapone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>Nitroprusside may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>Hydromorphone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00330</drugbank-id>
      <name>Ethambutol</name>
      <description>Ethambutol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>Metformin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00339</drugbank-id>
      <name>Pyrazinamide</name>
      <description>Pyrazinamide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00355</drugbank-id>
      <name>Aztreonam</name>
      <description>Aztreonam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>Chlorzoxazone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>Sulfadiazine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00364</drugbank-id>
      <name>Sucralfate</name>
      <description>Sucralfate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>Thiethylperazine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>Palonosetron may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00380</drugbank-id>
      <name>Dexrazoxane</name>
      <description>Dexrazoxane may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>Eszopiclone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>Alprazolam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Rosiglitazone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>Pramipexole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00415</drugbank-id>
      <name>Ampicillin</name>
      <description>Ampicillin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>Secobarbital may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>Methylphenidate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00432</drugbank-id>
      <name>Trifluridine</name>
      <description>Trifluridine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>Nitric Oxide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00437</drugbank-id>
      <name>Allopurinol</name>
      <description>Allopurinol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00441</drugbank-id>
      <name>Gemcitabine</name>
      <description>Gemcitabine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>Fosinopril may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>Flutamide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>Metolazone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00535</drugbank-id>
      <name>Cefdinir</name>
      <description>Cefdinir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00548</drugbank-id>
      <name>Azelaic acid</name>
      <description>Azelaic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00552</drugbank-id>
      <name>Pentostatin</name>
      <description>Pentostatin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>Methoxsalen may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00558</drugbank-id>
      <name>Zanamivir</name>
      <description>Zanamivir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>Fluocinolone acetonide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00597</drugbank-id>
      <name>Gadoteridol</name>
      <description>Gadoteridol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>Labetalol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>Clorazepic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Clofarabine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>Dexmedetomidine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00651</drugbank-id>
      <name>Dyphylline</name>
      <description>Dyphylline may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>Mecamylamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>Metaxalone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00665</drugbank-id>
      <name>Nilutamide</name>
      <description>Nilutamide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Chlorpropamide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>Galantamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>Midazolam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>Phentolamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>Furosemide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00698</drugbank-id>
      <name>Nitrofurantoin</name>
      <description>Nitrofurantoin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>Tamsulosin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00713</drugbank-id>
      <name>Oxacillin</name>
      <description>Oxacillin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00716</drugbank-id>
      <name>Nedocromil</name>
      <description>Nedocromil may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>Lisinopril may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>Thiabendazole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>Nateglinide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00733</drugbank-id>
      <name>Pralidoxime</name>
      <description>Pralidoxime may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>Gadobenic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00760</drugbank-id>
      <name>Meropenem</name>
      <description>Meropenem may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00761</drugbank-id>
      <name>Potassium chloride</name>
      <description>Potassium chloride may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>Methimazole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Propantheline may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00789</drugbank-id>
      <name>Gadopentetic acid</name>
      <description>Gadopentetic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>Perindopril may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>Fenoldopam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Dicyclomine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>Indapamide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00811</drugbank-id>
      <name>Ribavirin</name>
      <description>Ribavirin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>Tadalafil may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00828</drugbank-id>
      <name>Fosfomycin</name>
      <description>Fosfomycin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>Tolazamide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>Dobutamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>Oxazepam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>Dacarbazine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00853</drugbank-id>
      <name>Temozolomide</name>
      <description>Temozolomide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>Terbutaline may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Bumetanide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00894</drugbank-id>
      <name>Testolactone</name>
      <description>Testolactone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>Triazolam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Didanosine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00911</drugbank-id>
      <name>Tinidazole</name>
      <description>Tinidazole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>Amantadine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>Almotriptan may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00928</drugbank-id>
      <name>Azacitidine</name>
      <description>Azacitidine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>Maprotiline may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>Isoniazid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>Rizatriptan may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>Pindolol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00961</drugbank-id>
      <name>Mepivacaine</name>
      <description>Mepivacaine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>Zaleplon may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>Methyldopa may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>Ramelteon may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>Dopamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>Azathioprine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00995</drugbank-id>
      <name>Auranofin</name>
      <description>Auranofin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>Salbutamol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>Levobupivacaine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>Ganciclovir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01010</drugbank-id>
      <name>Edrophonium</name>
      <description>Edrophonium may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01011</drugbank-id>
      <name>Metyrapone</name>
      <description>Metyrapone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Sulfamethoxazole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>Guanfacine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>Isosorbide mononitrate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01022</drugbank-id>
      <name>Phylloquinone</name>
      <description>Phylloquinone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01024</drugbank-id>
      <name>Mycophenolic acid</name>
      <description>Mycophenolic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>Probenecid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Tolterodine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>Memantine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>Lubiprostone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01048</drugbank-id>
      <name>Abacavir</name>
      <description>Abacavir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01060</drugbank-id>
      <name>Amoxicillin</name>
      <description>Amoxicillin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>Glipizide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>Clonazepam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01093</drugbank-id>
      <name>Dimethyl sulfoxide</name>
      <description>Dimethyl sulfoxide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01099</drugbank-id>
      <name>Flucytosine</name>
      <description>Flucytosine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01101</drugbank-id>
      <name>Capecitabine</name>
      <description>Capecitabine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>Tolbutamide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01133</drugbank-id>
      <name>Tiludronic acid</name>
      <description>Tiludronic acid may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>Doxacurium may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>Flavoxate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>Bupropion may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01157</drugbank-id>
      <name>Trimetrexate</name>
      <description>Trimetrexate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>Guanethidine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01205</drugbank-id>
      <name>Flumazenil</name>
      <description>Flumazenil may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01213</drugbank-id>
      <name>Fomepizole</name>
      <description>Fomepizole may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>Estazolam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>Ketamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>Budesonide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>Metoclopramide may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01241</drugbank-id>
      <name>Gemfibrozil</name>
      <description>Gemfibrozil may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01249</drugbank-id>
      <name>Iodixanol</name>
      <description>Iodixanol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>Varenicline may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>Arformoterol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>Hydralazine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>Penbutolol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>Tiotropium may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01427</drugbank-id>
      <name>Amrinone</name>
      <description>Amrinone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01428</drugbank-id>
      <name>Oxybenzone</name>
      <description>Oxybenzone may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01550</drugbank-id>
      <name>Fenproporex</name>
      <description>Fenproporex may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>Bromazepam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>Chloral hydrate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>Metamfetamine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01610</drugbank-id>
      <name>Valganciclovir</name>
      <description>Valganciclovir may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>Sorbitol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01656</drugbank-id>
      <name>Roflumilast</name>
      <description>Roflumilast may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>Topiroxostat may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>Lorcaserin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04895</drugbank-id>
      <name>Pegaptanib</name>
      <description>Pegaptanib may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>Clevidipine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>Lofexidine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>Ezogabine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05018</drugbank-id>
      <name>Migalastat</name>
      <description>Migalastat may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>Brivaracetam may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>Apremilast may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06154</drugbank-id>
      <name>Pentaerythritol tetranitrate</name>
      <description>Pentaerythritol tetranitrate may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06186</drugbank-id>
      <name>Ipilimumab</name>
      <description>Ipilimumab may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06196</drugbank-id>
      <name>Icatibant</name>
      <description>Icatibant may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Alogliptin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06211</drugbank-id>
      <name>Doripenem</name>
      <description>Doripenem may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06230</drugbank-id>
      <name>Nalmefene</name>
      <description>Nalmefene may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>Droxidopa may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>Levocetirizine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Saxagliptin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>Telavancin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06623</drugbank-id>
      <name>Flupirtine</name>
      <description>Flupirtine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>Dalfampridine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06705</drugbank-id>
      <name>Gadofosveset trisodium</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06767</drugbank-id>
      <name>Ammonium chloride</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06782</drugbank-id>
      <name>Dimercaprol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Dimercaprol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06796</drugbank-id>
      <name>Mangafodipir</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Mangafodipir which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06800</drugbank-id>
      <name>Methylnaltrexone</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06809</drugbank-id>
      <name>Plerixafor</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Plerixafor which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Pralatrexate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06823</drugbank-id>
      <name>Tiopronin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Tiopronin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06824</drugbank-id>
      <name>Triethylenetetramine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08824</drugbank-id>
      <name>Ioflupane I-123</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08826</drugbank-id>
      <name>Deferiprone</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Deferiprone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08840</drugbank-id>
      <name>N-methylnicotinamide</name>
      <description>Dabigatran etexilate may decrease the excretion rate of N-methylnicotinamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08877</drugbank-id>
      <name>Ruxolitinib</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Peginesatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Aclidinium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08900</drugbank-id>
      <name>Teduglutide</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Teduglutide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Formestane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Trametinib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Macitentan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08964</drugbank-id>
      <name>Gemeprost</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Gemeprost which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Empagliflozin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09050</drugbank-id>
      <name>Ceftolozane</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Ceftolozane which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09066</drugbank-id>
      <name>Corifollitropin alfa</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Vortioxetine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Tasimelteon which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09081</drugbank-id>
      <name>Idebenone</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Idebenone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Vilanterol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Trimebutine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Tixocortol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09103</drugbank-id>
      <name>Ancestim</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Ancestim which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09106</drugbank-id>
      <name>Hydroxyethyl Starch</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09111</drugbank-id>
      <name>Pentastarch</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Pentastarch which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Stiripentol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09121</drugbank-id>
      <name>Aurothioglucose</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09129</drugbank-id>
      <name>Chromic chloride</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Chromic chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09132</drugbank-id>
      <name>Gadoteric acid</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09133</drugbank-id>
      <name>Iothalamic acid</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Iothalamic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09134</drugbank-id>
      <name>Ioversol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Ioversol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09135</drugbank-id>
      <name>Ioxilan</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Ioxilan which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09136</drugbank-id>
      <name>Isosulfan blue</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Isosulfan blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09137</drugbank-id>
      <name>Technetium Tc-99m mebrofenin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Technetium Tc-99m mebrofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09139</drugbank-id>
      <name>Technetium Tc-99m oxidronate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Technetium Tc-99m oxidronate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09148</drugbank-id>
      <name>Florbetaben (18F)</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09149</drugbank-id>
      <name>Florbetapir (18F)</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09156</drugbank-id>
      <name>Iopromide</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Iopromide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09163</drugbank-id>
      <name>Technetium Tc-99m exametazime</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09164</drugbank-id>
      <name>Technetium Tc-99m disofenin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Technetium Tc-99m disofenin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09165</drugbank-id>
      <name>Technetium Tc-99m pyrophosphate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Viloxazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Etoperidone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Lorpiprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Arotinolol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Moxisylyte which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09209</drugbank-id>
      <name>Pholcodine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Pholcodine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09210</drugbank-id>
      <name>Piracetam</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Piracetam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Bisoxatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Nicorandil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Blonanserin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Melperone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Tegafur which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09257</drugbank-id>
      <name>Gimeracil</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Gimeracil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Imidafenacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09264</drugbank-id>
      <name>Idarucizumab</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Idarucizumab which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Lixisenatide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Picosulfuric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09276</drugbank-id>
      <name>Sodium aurothiomalate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09277</drugbank-id>
      <name>Choline C 11</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Choline C 11 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Sacubitril which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09301</drugbank-id>
      <name>Chondroitin sulfate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09320</drugbank-id>
      <name>Procaine benzylpenicillin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09324</drugbank-id>
      <name>Sulbactam</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Sulbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09325</drugbank-id>
      <name>Sodium fluoride</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09338</drugbank-id>
      <name>Mersalyl</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Mersalyl which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09344</drugbank-id>
      <name>Invert sugar</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Invert sugar which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09357</drugbank-id>
      <name>Dexpanthenol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09394</drugbank-id>
      <name>Phosphoric acid</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Phosphoric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09395</drugbank-id>
      <name>Sodium acetate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Sodium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09407</drugbank-id>
      <name>Magnesium chloride</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Enalaprilat which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Acrivastine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09496</drugbank-id>
      <name>Octinoxate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Octinoxate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09502</drugbank-id>
      <name>Fludeoxyglucose (18F)</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09546</drugbank-id>
      <name>Iobenguane sulfate I-123</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Iobenguane sulfate I-123 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Ixazomib which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11077</drugbank-id>
      <name>Polyethylene glycol 400</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Polyethylene glycol 400 which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11090</drugbank-id>
      <name>Potassium nitrate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Potassium nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11098</drugbank-id>
      <name>Potassium bicarbonate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Potassium bicarbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11102</drugbank-id>
      <name>N-acetyltyrosine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11114</drugbank-id>
      <name>Eucalyptus oil</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11127</drugbank-id>
      <name>Selenious acid</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Selenious acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Opium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11135</drugbank-id>
      <name>Selenium</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Selenium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11136</drugbank-id>
      <name>Chromium</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Chromium which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11145</drugbank-id>
      <name>Oxyquinoline</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Pyrantel which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11164</drugbank-id>
      <name>Bicisate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Bicisate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11251</drugbank-id>
      <name>Tocopherol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Tocopherol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of DL-Methylephedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11328</drugbank-id>
      <name>Tetradecyl hydrogen sulfate (ester)</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11338</drugbank-id>
      <name>Clove oil</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Clove oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11358</drugbank-id>
      <name>Evening primrose oil</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Evening primrose oil which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11364</drugbank-id>
      <name>Pidotimod</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Pidotimod which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11560</drugbank-id>
      <name>Lesinurad</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Lesinurad which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11577</drugbank-id>
      <name>Indigotindisulfonic acid</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Etafedrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11691</drugbank-id>
      <name>Naldemedine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Naldemedine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Tropisetron which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Valbenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Delafloxacin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11989</drugbank-id>
      <name>Benznidazole</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Benznidazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12007</drugbank-id>
      <name>Isoflavone</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Isoflavone which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12107</drugbank-id>
      <name>Vaborbactam</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Vaborbactam which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Propiverine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12783</drugbank-id>
      <name>Benserazide</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Benserazide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Tiapride which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Levosalbutamol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13145</drugbank-id>
      <name>Nedaplatin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Nedaplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13156</drugbank-id>
      <name>Inosine pranobex</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13178</drugbank-id>
      <name>Inositol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Inositol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13185</drugbank-id>
      <name>Oxabolone cipionate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Oxabolone cipionate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13191</drugbank-id>
      <name>Phosphocreatine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Phosphocreatine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13269</drugbank-id>
      <name>Dichlorobenzyl alcohol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Ipecac which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13873</drugbank-id>
      <name>Fenofibric acid</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Bismuth subgallate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13967</drugbank-id>
      <name>Patent Blue</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Patent Blue which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14007</drugbank-id>
      <name>Pentetic acid</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Pentetic acid which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14184</drugbank-id>
      <name>Cinnamaldehyde</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Cinnamaldehyde which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14186</drugbank-id>
      <name>Cinnamyl alcohol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Cinnamyl alcohol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14498</drugbank-id>
      <name>Potassium acetate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Potassium acetate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Potassium sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14526</drugbank-id>
      <name>Chromic citrate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Chromic citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14527</drugbank-id>
      <name>Chromic nitrate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Chromic nitrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14528</drugbank-id>
      <name>Chromium gluconate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Chromium gluconate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14529</drugbank-id>
      <name>Chromium nicotinate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Chromium nicotinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14530</drugbank-id>
      <name>Chromous sulfate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Chromous sulfate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Solriamfetol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06815</drugbank-id>
      <name>Pyrithione</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Pyrithione which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11121</drugbank-id>
      <name>Chloroxylenol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11085</drugbank-id>
      <name>Resorcinol</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Resorcinol which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15593</drugbank-id>
      <name>Golodirsen</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Golodirsen which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00314</drugbank-id>
      <name>Capreomycin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Capreomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Codeine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Amitriptyline which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Imipramine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00512</drugbank-id>
      <name>Vancomycin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Vancomycin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Cisplatin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Pemetrexed which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00879</drugbank-id>
      <name>Emtricitabine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Emtricitabine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00982</drugbank-id>
      <name>Isotretinoin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Isotretinoin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Procainamide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Doxepin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Lithium cation which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Dimetacrine which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12615</drugbank-id>
      <name>Plazomicin</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Plazomicin which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Lithium hydroxide which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Lithium citrate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14508</drugbank-id>
      <name>Lithium succinate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Lithium succinate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>Dabigatran etexilate may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>Torasemide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Methyclothiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>Chlorthalidone may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>Ethoxzolamide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>Bendroflumethiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>Benzthiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>Amiloride may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>Cyclothiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>Eplerenone may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>Methazolamide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>Hydroflumethiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>Acetazolamide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>Chlorothiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>Trichlormethiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>Diazoxide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>Diclofenamide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>Polythiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>Quinethazone may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>Theobromine may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>Piretanide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>Tienilic acid may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05034</drugbank-id>
      <name>Ularitide</name>
      <description>Ularitide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>Indisulam may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>Azosemide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09015</drugbank-id>
      <name>Canrenoic acid</name>
      <description>Canrenoic acid may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>Efonidipine may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12221</drugbank-id>
      <name>Canrenone</name>
      <description>Canrenone may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12670</drugbank-id>
      <name>Rolofylline</name>
      <description>Rolofylline may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12704</drugbank-id>
      <name>Spiradoline</name>
      <description>Spiradoline may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>Cicletanine may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>Meticrane may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>Ibopamine may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>Mefruside may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>Mebutizide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>Cyclopenthiazide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>Clorexolone may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>Clofenamide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>Fenquizone may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>Clopamide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>Muzolimine may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>Xipamide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>Epitizide may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>Bromotheophylline may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14500</drugbank-id>
      <name>Potassium</name>
      <description>Potassium may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic acid</name>
      <description>The risk or severity of bleeding can be increased when Edetic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11268</drugbank-id>
      <name>Protocatechualdehyde</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Protocatechualdehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13124</drugbank-id>
      <name>Troxerutin</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Troxerutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00008</drugbank-id>
      <name>Peginterferon alfa-2a</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Peginterferon alfa-2a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00011</drugbank-id>
      <name>Interferon alfa-n1</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-n1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00018</drugbank-id>
      <name>Interferon alfa-n3</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-n3.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00033</drugbank-id>
      <name>Interferon gamma-1b</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon gamma-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00034</drugbank-id>
      <name>Interferon alfa-2a, Recombinant</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-2a, Recombinant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00056</drugbank-id>
      <name>Gemtuzumab ozogamicin</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Gemtuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00068</drugbank-id>
      <name>Interferon beta-1b</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon beta-1b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00069</drugbank-id>
      <name>Interferon alfacon-1</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfacon-1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00073</drugbank-id>
      <name>Rituximab</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Rituximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00087</drugbank-id>
      <name>Alemtuzumab</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Alemtuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00105</drugbank-id>
      <name>Interferon alfa-2b</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00112</drugbank-id>
      <name>Bevacizumab</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Bevacizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00120</drugbank-id>
      <name>Phenylalanine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Phenylalanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00242</drugbank-id>
      <name>Cladribine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Cladribine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00293</drugbank-id>
      <name>Raltitrexed</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Raltitrexed.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00309</drugbank-id>
      <name>Vindesine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Vindesine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Tioguanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Epirubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00488</drugbank-id>
      <name>Altretamine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Altretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Oxaliplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00859</drugbank-id>
      <name>Penicillamine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Penicillamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01008</drugbank-id>
      <name>Busulfan</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Busulfan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Mercaptopurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01073</drugbank-id>
      <name>Fludarabine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Fludarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01262</drugbank-id>
      <name>Decitabine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Decitabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01280</drugbank-id>
      <name>Nelarabine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Nelarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05258</drugbank-id>
      <name>Interferon alfa</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Interferon alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05472</drugbank-id>
      <name>omega interferon</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with omega interferon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Bendamustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08895</drugbank-id>
      <name>Tofacitinib</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Tofacitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09052</drugbank-id>
      <name>Blinatumomab</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Blinatumomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09122</drugbank-id>
      <name>Peginterferon beta-1a</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Peginterferon beta-1a.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12814</drugbank-id>
      <name>Cepeginterferon alfa-2B</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Cepeginterferon alfa-2B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The metabolism of Dabigatran etexilate can be decreased when combined with Phenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Dabigatran etexilate can be decreased when combined with Fosphenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Dabigatran etexilate can be decreased when combined with Eltrombopag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The excretion of Methotrexate can be decreased when combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00671</drugbank-id>
      <name>Cefixime</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Cefixime.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14725</drugbank-id>
      <name>Cefamandole nafate</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Cefamandole nafate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00254</drugbank-id>
      <name>Doxycycline</name>
      <description>The risk or severity of bleeding can be increased when Doxycycline is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The metabolism of Dabigatran etexilate can be decreased when combined with Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09539</drugbank-id>
      <name>Omega-3-acid ethyl esters</name>
      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01606</drugbank-id>
      <name>Tazobactam</name>
      <description>The risk or severity of bleeding can be increased when Tazobactam is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09079</drugbank-id>
      <name>Nintedanib</name>
      <description>The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Nintedanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of bleeding can be increased when Escitalopram is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Indinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Liothyronine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Digoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00428</drugbank-id>
      <name>Streptozocin</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Streptozocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Trimethoprim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Levothyroxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00615</drugbank-id>
      <name>Rifabutin</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Rifabutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Amprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Oxcarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Liotrix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02261</drugbank-id>
      <name>Platelet Activating Factor</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Platelet Activating Factor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02659</drugbank-id>
      <name>Cholic Acid</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Cholic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04573</drugbank-id>
      <name>Estriol</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Estriol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Tesmilifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Etravirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09280</drugbank-id>
      <name>Lumacaftor</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Lumacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The serum concentration of Dabigatran etexilate can be decreased when it is combined with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00027</drugbank-id>
      <name>Gramicidin D</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Gramicidin D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sildenafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Azithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Pantoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lovastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Reboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00276</drugbank-id>
      <name>Amsacrine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Amsacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Venlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00300</drugbank-id>
      <name>Tenofovir disoproxil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tenofovir disoproxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Acetaminophen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Gefitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Dihydroergotamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Terfenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Protriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Mefloquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00360</drugbank-id>
      <name>Sapropterin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sapropterin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Nisoldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Loxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Prazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Buspirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Albendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00520</drugbank-id>
      <name>Caspofungin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Caspofungin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00602</drugbank-id>
      <name>Ivermectin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ivermectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Amodiaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Testosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Astemizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Simvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Pentazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Losartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Flurazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ergotamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Esomeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Scopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Candesartan cilexetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fentanyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00845</drugbank-id>
      <name>Clofazimine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Clofazimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Vardenafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Conivaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Flupentixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Metronidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00970</drugbank-id>
      <name>Dactinomycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Dactinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Selegiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01039</drugbank-id>
      <name>Fenofibrate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fenofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Nitrendipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Atorvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01103</drugbank-id>
      <name>Quinacrine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Quinacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Miconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01117</drugbank-id>
      <name>Atovaquone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Atovaquone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Bicalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01196</drugbank-id>
      <name>Estramustine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Estramustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01212</drugbank-id>
      <name>Ceftriaxone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ceftriaxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Clomipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lapatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Posaconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Darunavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fosamprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01329</drugbank-id>
      <name>Cefoperazone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cefoperazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02010</drugbank-id>
      <name>Staurosporine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Staurosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02587</drugbank-id>
      <name>Colforsin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Colforsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04216</drugbank-id>
      <name>Quercetin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Quercetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04348</drugbank-id>
      <name>Taurocholic acid</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Taurocholic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04540</drugbank-id>
      <name>Cholesterol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cholesterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04851</drugbank-id>
      <name>Biricodar</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Biricodar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04877</drugbank-id>
      <name>Voacamine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Voacamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04881</drugbank-id>
      <name>Elacridar</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Elacridar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04960</drugbank-id>
      <name>Tipifarnib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tipifarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Telaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06191</drugbank-id>
      <name>Zosuquidar</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Zosuquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06212</drugbank-id>
      <name>Tolvaptan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tolvaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06240</drugbank-id>
      <name>Tariquidar</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tariquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06420</drugbank-id>
      <name>Annamycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Annamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06448</drugbank-id>
      <name>Lonafarnib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lonafarnib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Isavuconazonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06733</drugbank-id>
      <name>Bafilomycin A1</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Bafilomycin A1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06734</drugbank-id>
      <name>Bafilomycin B1</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Bafilomycin B1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Benzyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cabazitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07348</drugbank-id>
      <name>Brefeldin A</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Brefeldin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08820</drugbank-id>
      <name>Ivacaftor</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ivacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08827</drugbank-id>
      <name>Lomitapide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lomitapide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Boceprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fidaxomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Linagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Mirabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ponatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08916</drugbank-id>
      <name>Afatinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Afatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09027</drugbank-id>
      <name>Ledipasvir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ledipasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Suvorexant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Eliglustat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Netupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09102</drugbank-id>
      <name>Daclatasvir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Daclatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Polyethylene glycol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Rolapitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Paritaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Glycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11363</drugbank-id>
      <name>Alectinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Alectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11387</drugbank-id>
      <name>Chloroform</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Chloroform.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11430</drugbank-id>
      <name>Monensin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Monensin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11544</drugbank-id>
      <name>Salinomycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Salinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Venetoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Asunaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11613</drugbank-id>
      <name>Velpatasvir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Velpatasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Pitolisant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11712</drugbank-id>
      <name>Tezacaftor</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tezacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11828</drugbank-id>
      <name>Neratinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Neratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11869</drugbank-id>
      <name>Valspodar</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Valspodar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Glasdegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Abemaciclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Alpelisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Voxilaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12035</drugbank-id>
      <name>Sarecycline</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sarecycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Letermovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12147</drugbank-id>
      <name>Erdafitinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Erdafitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12582</drugbank-id>
      <name>Piperine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Piperine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12799</drugbank-id>
      <name>Laniquidar</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Laniquidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13125</drugbank-id>
      <name>Lusutrombopag</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lusutrombopag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13179</drugbank-id>
      <name>Troleandomycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Troleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13878</drugbank-id>
      <name>Pibrentasvir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Pibrentasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13879</drugbank-id>
      <name>Glecaprevir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Glecaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Testosterone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Testosterone enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Testosterone undecanoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14056</drugbank-id>
      <name>Nigericin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Nigericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14057</drugbank-id>
      <name>Valinomycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Valinomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14061</drugbank-id>
      <name>Hycanthone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Hycanthone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14062</drugbank-id>
      <name>Concanamycin A</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Concanamycin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14067</drugbank-id>
      <name>Dofequidar</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Dofequidar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14069</drugbank-id>
      <name>ONT-093</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with ONT-093.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14070</drugbank-id>
      <name>HM-30181</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with HM-30181.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14071</drugbank-id>
      <name>Desmethylsertraline</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Desmethylsertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14072</drugbank-id>
      <name>Reversin 121</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Reversin 121.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ivosidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12500</drugbank-id>
      <name>Fedratinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fedratinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Istradefylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lasmiditan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Raloxifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Clonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Trimipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Olopatadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tegaserod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Digitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14126</drugbank-id>
      <name>Tenofovir</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tenofovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Donepezil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08860</drugbank-id>
      <name>Pitavastatin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Pitavastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Flecainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01217</drugbank-id>
      <name>Anastrozole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Anastrozole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Loratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fexofenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13007</drugbank-id>
      <name>Enfortumab vedotin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Enfortumab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14962</drugbank-id>
      <name>Trastuzumab deruxtecan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Trastuzumab deruxtecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12941</drugbank-id>
      <name>Darolutamide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Darolutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00126</drugbank-id>
      <name>Ascorbic acid</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ascorbic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00175</drugbank-id>
      <name>Pravastatin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Pravastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Eletriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cabergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Topiramate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00291</drugbank-id>
      <name>Chlorambucil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Chlorambucil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Morphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00305</drugbank-id>
      <name>Mitomycin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Mitomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Clobazam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cerivastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00480</drugbank-id>
      <name>Lenalidomide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lenalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00495</drugbank-id>
      <name>Zidovudine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Zidovudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00523</drugbank-id>
      <name>Alitretinoin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Alitretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lamotrigine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sumatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Lamivudine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Tetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Diazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00882</drugbank-id>
      <name>Clomifene</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Clomifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ezetimibe.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00987</drugbank-id>
      <name>Cytarabine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cytarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01042</drugbank-id>
      <name>Melphalan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Melphalan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Naloxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Levetiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sitagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Neostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ketazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03203</drugbank-id>
      <name>Sphingosine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Sphingosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03825</drugbank-id>
      <name>Rhodamine 6G</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Rhodamine 6G.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04690</drugbank-id>
      <name>Camptothecin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Camptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Debrisoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05015</drugbank-id>
      <name>Belinostat</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Belinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Indacaterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05239</drugbank-id>
      <name>Cobimetinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Cobimetinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05889</drugbank-id>
      <name>Inotuzumab ozogamicin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Inotuzumab ozogamicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Romidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Silodosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ambrisentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Prucalopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Axitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06670</drugbank-id>
      <name>Odanacatib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Odanacatib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The serum concentration of Fesoterodine can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08828</drugbank-id>
      <name>Vismodegib</name>
      <description>The serum concentration of Vismodegib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08889</drugbank-id>
      <name>Carfilzomib</name>
      <description>The serum concentration of Carfilzomib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The serum concentration of Fluticasone furoate can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The serum concentration of Pomalidomide can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The serum concentration of Dabrafenib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08930</drugbank-id>
      <name>Dolutegravir</name>
      <description>The serum concentration of Dolutegravir can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08934</drugbank-id>
      <name>Sofosbuvir</name>
      <description>The serum concentration of Sofosbuvir can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The serum concentration of Ceritinib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The serum concentration of Umeclidinium can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The serum concentration of Lenvatinib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09099</drugbank-id>
      <name>Somatostatin</name>
      <description>The serum concentration of Somatostatin can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09161</drugbank-id>
      <name>Technetium Tc-99m sestamibi</name>
      <description>The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The serum concentration of Dasabuvir can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The serum concentration of Ubidecarenone can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09296</drugbank-id>
      <name>Ombitasvir</name>
      <description>The serum concentration of Ombitasvir can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The serum concentration of Osimertinib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The serum concentration of Selexipag can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11431</drugbank-id>
      <name>Moxidectin</name>
      <description>The serum concentration of Moxidectin can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11447</drugbank-id>
      <name>Phenothiazine</name>
      <description>The serum concentration of Phenothiazine can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11574</drugbank-id>
      <name>Elbasvir</name>
      <description>The serum concentration of Elbasvir can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11575</drugbank-id>
      <name>Grazoprevir</name>
      <description>The serum concentration of Grazoprevir can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11641</drugbank-id>
      <name>Vinflunine</name>
      <description>The serum concentration of Vinflunine can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11760</drugbank-id>
      <name>Talazoparib</name>
      <description>The serum concentration of Talazoparib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The serum concentration of Talinolol can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The serum concentration of Baricitinib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The serum concentration of Ertugliflozin can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The serum concentration of Revefenacin can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11952</drugbank-id>
      <name>Duvelisib</name>
      <description>The serum concentration of Duvelisib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The serum concentration of Elagolix can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11995</drugbank-id>
      <name>Avatrombopag</name>
      <description>The serum concentration of Avatrombopag can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The serum concentration of Gilteritinib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The serum concentration of Bromperidol can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12455</drugbank-id>
      <name>Omadacycline</name>
      <description>The serum concentration of Omadacycline can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The serum concentration of Copanlisib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12836</drugbank-id>
      <name>Grapiprant</name>
      <description>The serum concentration of Grapiprant can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13146</drugbank-id>
      <name>Fluciclovine (18F)</name>
      <description>The serum concentration of Fluciclovine (18F) can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13173</drugbank-id>
      <name>Cerliponase alfa</name>
      <description>The serum concentration of Cerliponase alfa can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The serum concentration of Fluticasone can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The serum concentration of Estradiol dienanthate can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14723</drugbank-id>
      <name>Larotrectinib</name>
      <description>The serum concentration of Larotrectinib can be increased when it is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Ranolazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The serum concentration of Dabigatran etexilate can be increased when it is combined with Isavuconazole.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.17</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>4.66e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.59</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>ethyl 3-(1-{2-[({4-[(1E)-amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>ethyl 3-(1-{2-[({4-[(1E)-amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>627.7332</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>627.316917457</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C34H41N7O5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>KSGXQBZTULBEEQ-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>154.03</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>176.43</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>70.65</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>17</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>17.89</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>4.48</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1.8mg/ml, partly soluble </value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>132</value>
      <source>http://www.chemspider.com/Chemical-Structure.8615298.html</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>3.8</value>
      <source>Apotex Inc. Product Monograph: Dabigatran Etexilate</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20301</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>70746</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>6445226</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>99443249</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D07144</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4948999</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50432209</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA165958369</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Dabigatran</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL539697</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/pradaxa-drug.htm</url>
    </external-link>
    <external-link>
      <resource>PDRhealth</resource>
      <url>http://www.pdrhealth.com/drugs/pradaxa</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/dabigatran.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB06695</drugbank-id>
        <name>Dabigatran etexilate</name>
      </left-element>
      <right-element>
        <drugbank-id>DB14726</drugbank-id>
        <name>Dabigatran</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB14726</drugbank-id>
        <name>Dabigatran</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02413</drugbank-id>
        <name>Dabigatran 1-O-acylglucuronide metabolite</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0003538</drugbank-id>
          <name>UDP-glucuronosyltransferase 1-9</name>
          <uniprot-id>O60656</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0003679</drugbank-id>
          <name>UDP-glucuronosyltransferase 2B7</name>
          <uniprot-id>P16662</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0004696</drugbank-id>
          <name>UDP-glucuronosyltransferase 2B15</name>
          <uniprot-id>P54855</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB14726</drugbank-id>
        <name>Dabigatran</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02414</drugbank-id>
        <name>Dabigatran 2-O-acylglucuronide metabolite</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB14726</drugbank-id>
        <name>Dabigatran</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02415</drugbank-id>
        <name>Dabigatran 3-O-acylglucuronide metabolite</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DB14726</drugbank-id>
        <name>Dabigatran</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02416</drugbank-id>
        <name>Dabigatran 4-O-acylglucuronide metabolite</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000048</id>
      <name>Prothrombin</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15265</ref-id>
            <pubmed-id>19756950</pubmed-id>
            <citation>Squizzato A, Dentali F, Steidl L, Ageno W: New direct thrombin inhibitors. Intern Emerg Med. 2009 Dec;4(6):479-84. doi: 10.1007/s11739-009-0314-8. Epub 2009 Sep 15.</citation>
          </article>
          <article>
            <ref-id>A15266</ref-id>
            <pubmed-id>17061960</pubmed-id>
            <citation>Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J: Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006 Nov;62(5):527-37.</citation>
          </article>
          <article>
            <ref-id>A15267</ref-id>
            <pubmed-id>20424539</pubmed-id>
            <citation>Karthikeyan G, Eikelboom JW, Hirsh J: Dabigatran: ready for prime time? Pol Arch Med Wewn. 2010 Apr;120(4):137-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P00734" source="Swiss-Prot">
        <name>Prothrombin</name>
        <general-function>Thrombospondin receptor activity</general-function>
        <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.</specific-function>
        <gene-name>F2</gene-name>
        <locus>11p11-q12</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi>5.7</theoretical-pi>
        <molecular-weight>70036.295</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3535</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>F2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M17262</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>339641</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2362</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P00734</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>THRB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.5</synonym>
          <synonym>Coagulation factor II</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016004|Prothrombin
MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016005|Prothrombin (F2)
ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC
GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG
ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
GGAGAGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00594</identifier>
            <name>Gla</name>
          </pfam>
          <pfam>
            <identifier>PF00051</identifier>
            <name>Kringle</name>
          </pfam>
          <pfam>
            <identifier>PF00089</identifier>
            <name>Trypsin</name>
          </pfam>
          <pfam>
            <identifier>PF09396</identifier>
            <name>Thrombin_light</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>growth factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thrombospondin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute-phase response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation, intrinsic pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytosolic calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibrinolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organismal development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of astrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fibrinolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-glutamic acid carboxylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of collagen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of reactive oxygen species metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-translational protein modification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell shape</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to inactivity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to wounding</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="3">
      <id>BE0002705</id>
      <name>Liver carboxylesterase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17923</ref-id>
            <pubmed-id>23239178</pubmed-id>
            <citation>Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P23141" source="Swiss-Prot">
        <name>Liver carboxylesterase 1</name>
        <general-function>Triglyceride lipase activity</general-function>
        <specific-function>Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity, catalyzing the ethyl esterification of oleic acid to ethyloleate.</specific-function>
        <gene-name>CES1</gene-name>
        <locus>16q13-q22.1</locus>
        <cellular-location>Endoplasmic reticulum lumen</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-17</signal-regions>
        <theoretical-pi>6.58</theoretical-pi>
        <molecular-weight>62520.62</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1863</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CES1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M73499</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2592</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P23141</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>EST1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ACAT</synonym>
          <synonym>Acyl-coenzyme A:cholesterol acyltransferase</synonym>
          <synonym>Brain carboxylesterase hBr1</synonym>
          <synonym>Carboxylesterase 1</synonym>
          <synonym>CE-1</synonym>
          <synonym>CES2</synonym>
          <synonym>Cocaine carboxylesterase</synonym>
          <synonym>Egasyn</synonym>
          <synonym>hCE-1</synonym>
          <synonym>HMSE</synonym>
          <synonym>Methylumbelliferyl-acetate deacetylase 1</synonym>
          <synonym>Monocyte/macrophage serine esterase</synonym>
          <synonym>REH</synonym>
          <synonym>Retinyl ester hydrolase</synonym>
          <synonym>Serine esterase 1</synonym>
          <synonym>SES1</synonym>
          <synonym>TGH</synonym>
          <synonym>Triacylglycerol hydrolase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0005305|Liver carboxylesterase 1
MWLRAFILATLSASAAWGHPSSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPL
GPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLN
IYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFST
GDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNLF
HRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLK
MKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIP
MQLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDL
IADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPF
LKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLK
DKEVAFWTNLFAKKAVEKPPQTEHIEL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021334|Liver carboxylesterase 1 (CES1)
ATGTGGCTCCGTGCCTTTATCCTGGCCACTCTCTCTGCTTCCGCGGCTTGGGGGCATCCG
TCCTCGCCACCTGTGGTGGACACCGTGCATGGCAAAGTGCTGGGGAAGTTCGTCAGCTTA
GAAGGATTTGCACAGCCTGTGGCCATTTTCCTGGGAATCCCTTTTGCCAAGCCGCCTCTT
GGACCCCTGAGGTTTACTCCACCGCAGCCTGCAGAACCATGGAGCTTTGTGAAGAATGCC
ACCTCGTACCCTCCTATGTGCACCCAAGATCCCAAGGCGGGGCAGTTACTCTCAGAGCTA
TTTACAAACCGAAAGGAGAACATTCCTCTCAAGCTTTCTGAAGACTGTCTTTACCTCAAT
ATTTACACTCCTGCTGACTTGACCAAGAAAAACAGGCTGCCGGTGATGGTGTGGATCCAC
GGAGGGGGGCTGATGGTGGGTGCGGCATCAACCTATGATGGGCTGGCCCTTGCTGCCCAT
GAAAACGTGGTGGTGGTGACCATTCAATATCGCCTGGGCATCTGGGGATTCTTCAGCACA
GGGGATGAACACAGCCGGGGGAACTGGGGTCACCTGGACCAGGTGGCTGCCCTGCGCTGG
GTCCAGGACAACATTGCCAGCTTTGGAGGGAACCCAGGCTCTGTGACCATCTTTGGAGAG
TCAGCGGGAGGAGAAAGTGTCTCTGTTCTTGTTTTGTCTCCATTGGCCAAGAACCTCTTC
CACCGGGCCATTTCTGAGAGTGGCGTGGCCCTCACTTCTGTTCTGGTGAAGAAAGGTGAT
GTCAAGCCCTTGGCTGAGCAAATTGCTATCACTGCTGGGTGCAAAACCACCACCTCTGCT
GTCATGGTTCACTGCCTGCGACAGAAGACGGAAGAGGAGCTCTTGGAGACGACATTGAAA
ATGAAATTCTTATCTCTGGACTTACAGGGAGACCCCAGAGAGAGTCAACCCCTTCTGGGC
ACTGTGATTGATGGGATGCTGCTGCTGAAAACACCTGAAGAGCTTCAAGCTGAAAGGAAT
TTCCACACTGTCCCCTACATGGTCGGAATTAACAAGCAGGAGTTTGGCTGGTTGATTCCA
ATGCAGTTGATGAGCTATCCACTCTCCGAAGGGCAACTGGACCAGAAGACAGCCATGTCA
CTCCTGTGGAAGTCCTATCCCCTTGTTTGCATTGCTAAGGAACTGATTCCAGAAGCCACT
GAGAAATACTTAGGAGGAACAGACGACACTGTCAAAAAGAAAGACCTGTTCCTGGACTTG
ATAGCAGATGTGATGTTTGGTGTCCCATCTGTGATTGTGGCCCGGAACCACAGAGATGCT
GGAGCACCCACCTACATGTATGAGTTTCAGTACCGTCCAAGCTTCTCATCAGACATGAAA
CCCAAGACGGTGATAGGAGACCACGGGGATGAGCTCTTCTCCGTCTTTGGGGCCCCATTT
TTAAAAGAGGGTGCCTCAGAAGAGGAGATCAGACTTAGCAAGATGGTGATGAAATTCTGG
GCCAACTTTGCTCGCAATGGAAACCCCAATGGGGAAGGGCTGCCCCACTGGCCAGAGTAC
AACCAGAAGGAAGGGTATCTGCAGATTGGTGCCAACACCCAGGCGGCCCAGAAGCTGAAG
GACAAAGAAGTAGCTTTCTGGACCAACCTCTTTGCCAAGAAGGCAGTGGAGAAGCCACCC
CAGACAGAACACATAGAGCTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00135</identifier>
            <name>COesterase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carboxylic ester hydrolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>methylumbelliferyl-acetate deacetylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>sterol esterase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>triglyceride lipase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="4">
      <id>BE0004712</id>
      <name>Cocaine esterase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17923</ref-id>
            <pubmed-id>23239178</pubmed-id>
            <citation>Hu ZY, Parker RB, Herring VL, Laizure SC: Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704. doi: 10.1007/s00216-012-6576-4. Epub 2012 Dec 14.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O00748" source="Swiss-Prot">
        <name>Cocaine esterase</name>
        <general-function>Methylumbelliferyl-acetate deacetylase activity</general-function>
        <specific-function>Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and 6-monoacetylmorphine.</specific-function>
        <gene-name>CES2</gene-name>
        <locus/>
        <cellular-location>Endoplasmic reticulum lumen</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-26</signal-regions>
        <theoretical-pi/>
        <molecular-weight>61806.41</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1864</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O00748</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>EST2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.1.84</synonym>
          <synonym>Carboxylesterase 2</synonym>
          <synonym>CE-2</synonym>
          <synonym>hCE-2</synonym>
          <synonym>ICE</synonym>
          <synonym>Methylumbelliferyl-acetate deacetylase 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008563|Cocaine esterase
MRLHRLRARLSAVACGLLLLLVRGQGQDSASPIRTTHTGQVLGSLVHVKGANAGVQTFLG
IPFAKPPLGPLRFAPPEPPESWSGVRDGTTHPAMCLQDLTAVESEFLSQFNMTFPSDSMS
EDCLYLSIYTPAHSHEGSNLPVMVWIHGGALVFGMASLYDGSMLAALENVVVVIIQYRLG
VLGFFSTGDKHATGNWGYLDQVAALRWVQQNIAHFGGNPDRVTIFGESAGGTSVSSLVVS
PISQGLFHGAIMESGVALLPGLIASSADVISTVVANLSACDQVDSEALVGCLRGKSKEEI
LAINKPFKMIPGVVDGVFLPRHPQELLASADFQPVPSIVGVNNNEFGWLIPKVMRIYDTQ
KEMDREASQAALQKMLTLLMLPPTFGDLLREEYIGDNGDPQTLQAQFQEMMADSMFVIPA
LQVAHFQCSRAPVYFYEFQHQPSWLKNIRPPHMKADHGDELPFVFRSFFGGNYIKFTEEE
EQLSRKMMKYWANFARNGNPNGEGLPHWPLFDQEEQYLQLNLQPAVGRALKAHRLQFWKK
ALPQKIQELEEPEERHTEL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013276|Cocaine esterase (CES2)
ATGACTGCTCAGTCCCGCTCTCCTACCACACCCACCTTTCCCGGCCCAAGCCAGCGCACC
CCGCTGACTCCCTGCCCAGTCCAAACTCCAAGGCTGGGCAAGGCACTGATCCACTGCTGG
ACAGACCCGGGGCAGCCTCTGGGTGAACAGCAGCGTGTCCGCCGGCAGCGAACCGAGACC
AGCGAGCCGACCATGCGGCTGCACAGACTTCGTGCGCGGCTGAGCGCGGTGGCCTGTGGG
CTTCTGCTGCTTCTTGTCCGGGGCCAGGGCCAGGACTCAGCCAGTCCCATCCGGACCACA
CACACGGGGCAGGTGCTGGGGAGTCTTGTCCATGTGAAGGGCGCCAATGCCGGGGTCCAA
ACCTTCCTGGGAATTCCATTTGCCAAGCCACCTCTAGGTCCGCTGCGATTTGCACCCCCT
GAGCCCCCTGAATCTTGGAGTGGTGTGAGGGATGGAACCACCCATCCGGCCATGTGTCTA
CAGGACCTCACCGCAGTGGAGTCAGAGTTTCTTAGCCAGTTCAACATGACCTTCCCTTCC
GACTCCATGTCTGAGGACTGCCTGTACCTCAGCATCTACACGCCGGCCCATAGCCATGAA
GGCTCTAACCTGCCGGTGATGGTGTGGATCCACGGTGGTGCGCTTGTTTTTGGCATGGCT
TCCTTGTATGATGGTTCCATGCTGGCTGCCTTGGAGAACGTGGTGGTGGTCATCATCCAG
TACCGCCTGGGTGTCCTGGGCTTCTTCAGCACTGGAGACAAGCACGCAACCGGCAACTGG
GGCTACCTGGACCAAGTGGCTGCACTACGCTGGGTCCAGCAGAATATCGCCCACTTTGGA
GGCAACCCTGACCGTGTCACCATTTTTGGCGAGTCTGCGGGTGGCACGAGTGTGTCTTCG
CTTGTTGTGTCCCCCATATCCCAAGGACTCTTCCACGGAGCCATCATGGAGAGTGGCGTG
GCCCTCCTGCCCGGCCTCATTGCCAGCTCAGCTGATGTCATCTCCACGGTGGTGGCCAAC
CTGTCTGCCTGTGACCAAGTTGACTCTGAGGCCCTGGTGGGCTGCCTGCGGGGCAAGAGT
AAAGAGGAGATTCTTGCAATTAACAAGCCTTTCAAGATGATCCCCGGAGTGGTGGATGGG
GTCTTCCTGCCCAGGCACCCCCAGGAGCTGCTGGCCTCTGCCGACTTTCAGCCTGTCCCT
AGCATTGTTGGTGTCAACAACAATGAATTCGGCTGGCTCATCCCCAAGGTCATGAGGATC
TATGATACCCAGAAGGAAATGGACAGAGAGGCCTCCCAGGCTGCTCTGCAGAAAATGTTA
ACGCTGCTGATGTTGCCTCCTACATTTGGTGACCTGCTGAGGGAGGAGTACATTGGGGAC
AATGGGGATCCCCAGACCCTCCAAGCGCAGTTCCAGGAGATGATGGCGGACTCCATGTTT
GTGATCCCTGCACTCCAAGTAGCACATTTTCAGTGTTCCCGGGCCCCTGTGTACTTCTAC
GAGTTCCAGCATCAGCCCAGCTGGCTCAAGAACATCAGGCCACCGCACATGAAGGCAGAC
CATGGTGATGAGCTTCCTTTTGTTTTCAGAAGTTTCTTTGGGGGCAACTACATTAAATTC
ACTGAGGAAGAGGAGCAGCTAAGCAGGAAGATGATGAAGTACTGGGCCAACTTTGCGAGA
AATGGGAACCCCAATGGCGAGGGTCTGCCACACTGGCCGCTGTTCGACCAGGAGGAGCAA
TACCTGCAGCTGAACCTACAGCCTGCGGTGGGCCGGGCTCTGAAGGCCCACAGGCTCCAG
TTCTGGAAGAAGGCGCTGCCCCAAAAGATCCAGGAGCTCGAGGAGCCTGAAGAGAGACAC
ACAGAGCTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00135</identifier>
            <name>COesterase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carboxylic ester hydrolase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>methylumbelliferyl-acetate deacetylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="5">
      <id>BE0003538</id>
      <name>UDP-glucuronosyltransferase 1-9</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17924</ref-id>
            <pubmed-id>20551237</pubmed-id>
            <citation>Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O60656" source="Swiss-Prot">
        <name>UDP-glucuronosyltransferase 1-9</name>
        <general-function>Retinoic acid binding</general-function>
        <specific-function>UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.</specific-function>
        <gene-name>UGT1A9</gene-name>
        <locus>2q37</locus>
        <cellular-location>Microsome</cellular-location>
        <transmembrane-regions>488-504</transmembrane-regions>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>7.96</theoretical-pi>
        <molecular-weight>59940.495</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12541</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S55985</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7690346</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O60656</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UD19_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.17</synonym>
          <synonym>GNT1</synonym>
          <synonym>lugP4</synonym>
          <synonym>UDP-glucuronosyltransferase 1-I</synonym>
          <synonym>UDP-glucuronosyltransferase 1A9</synonym>
          <synonym>UDPGT 1-9</synonym>
          <synonym>UGT-1I</synonym>
          <synonym>UGT1</synonym>
          <synonym>UGT1I</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006817|UDP-glucuronosyltransferase 1-9
MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLILRGHEVVVVMP
EVSWQLGRSLNCTVKTYSTSYTLEDLDREFKAFAHAQWKAQVRSIYSLLMGSYNDIFDLF
FSNCRSLFKDKKLVEYLKESSFDAVFLDPFDNCGLIVAKYFSLPSVVFARGILCHYLEEG
AQCPAPLSYVPRILLGFSDAMTFKERVRNHIMHLEEHLLCHRFFKNALEIASEILQTPVT
EYDLYSHTSIWLLRTDFVLDYPKPVMPNMIFIGGINCHQGKPLPMEFEAYINASGEHGIV
VFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGH
PMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDL
ENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTW
YQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012464|UDP-glucuronosyltransferase 1-9 (UGT1A9)
ATGGCTTGCACAGGGTGGACCAGCCCCCTTCCTCTATGTGTGTGTCTGCTGCTGACCTGT
GGCTTTGCCGAGGCAGGGAAGCTACTGGTAGTGCCCATGGATGGGAGCCACTGGTTCACC
ATGAGGTCGGTGGTGGAGAAACTCATTCTCAGGGGGCATGAGGTGGTTGTAGTCATGCCA
GAGGTGAGTTGGCAACTGGGAAGATCACTGAATTGCACAGTGAAGACTTATTCAACTTCA
TATACCCTGGAGGATCTGGACCGGGAGTTCAAGGCTTTTGCCCATGCTCAATGGAAAGCA
CAAGTACGAAGTATATATTCTCTATTAATGGGTTCATACAATGACATTTTTGACTTATTT
TTTTCAAATTGCAGGAGTTTGTTTAAAGACAAAAAATTAGTAGAATACTTAAAGGAGAGT
TCTTTTGATGCAGTGTTTCTCGATCCTTTTGATAACTGTGGCTTAATTGTTGCCAAATAT
TTCTCCCTCCCCTCCGTGGTCTTCGCCAGGGGAATACTTTGCCACTATCTTGAAGAAGGT
GCACAGTGCCCTGCTCCTCTTTCCTATGTCCCCAGAATTCTCTTAGGGTTCTCAGATGCC
ATGACTTTCAAGGAGAGAGTACGGAACCACATCATGCACTTGGAGGAACATTTATTATGC
CACCGTTTTTTCAAAAATGCCCTAGAAATAGCCTCTGAAATTCTCCAAACACCTGTTACG
GAGTATGATCTCTACAGCCACACATCAATTTGGTTGTTGCGAACGGACTTTGTTTTGGAC
TATCCCAAACCCGTGATGCCCAACATGATCTTCATTGGTGGTATCAACTGCCATCAGGGA
AAGCCGTTGCCTATGGAATTTGAAGCCTACATTAATGCTTCTGGAGAACATGGAATTGTG
GTTTTCTCTTTGGGATCAATGGTCTCAGAAATTCCAGAGAAGAAAGCTATGGCAATTGCT
GATGCTTTGGGCAAAATCCCTCAGACAGTCCTGTGGCGGTACACTGGAACCCGACCATCG
AATCTTGCGAACAACACGATACTTGTTAAGTGGCTACCCCAAAACGATCTGCTTGGTCAC
CCGATGACCCGTGCCTTTATCACCCATGCTGGTTCCCATGGTGTTTATGAAAGCATATGC
AATGGCGTTCCCATGGTGATGATGCCCTTGTTTGGTGATCAGATGGACAATGCAAAGCGC
ATGGAGACTAAGGGAGCTGGAGTGACCCTGAATGTTCTGGAAATGACTTCTGAAGATTTA
GAAAATGCTCTAAAAGCAGTCATCAATGACAAAAGTTACAAGGAGAACATCATGCGCCTC
TCCAGCCTTCACAAGGACCGCCCGGTGGAGCCGCTGGACCTGGCCGTGTTCTGGGTGGAG
TTTGTGATGAGGCACAAGGGCGCGCCACACCTGCGCCCCGCAGCCCACGACCTCACCTGG
TACCAGTACCATTCCTTGGACGTGATTGGTTTCCTCTTGGCCGTCGTGCTGACAGTGGCC
TTCATCACCTTTAAATGTTGTGCTTATGGCTACCGGAAATGCTTGGGGAAAAAAGGGCGA
GTTAAGAAAGCCCACAAATCCAAGACCCATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00201</identifier>
            <name>UDPGT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>retinoic acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavone metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of fatty acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retinoic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="6">
      <id>BE0003679</id>
      <name>UDP-glucuronosyltransferase 2B7</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17924</ref-id>
            <pubmed-id>20551237</pubmed-id>
            <citation>Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16662" source="Swiss-Prot">
        <name>UDP-glucuronosyltransferase 2B7</name>
        <general-function>Glucuronosyltransferase activity</general-function>
        <specific-function>UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol (in vitro).</specific-function>
        <gene-name>UGT2B7</gene-name>
        <locus>4q13</locus>
        <cellular-location>Microsome membrane</cellular-location>
        <transmembrane-regions>493-509</transmembrane-regions>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi>8.45</theoretical-pi>
        <molecular-weight>60694.12</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12554</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J05428</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>340080</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16662</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UD2B7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.17</synonym>
          <synonym>3,4-catechol estrogen-specific UDPGT</synonym>
          <synonym>UDP-glucuronosyltransferase 2B9</synonym>
          <synonym>UDPGT 2B7</synonym>
          <synonym>UDPGT 2B9</synonym>
          <synonym>UDPGTh-2</synonym>
          <synonym>UGTB2B9</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012557|UDP-glucuronosyltransferase 2B7
MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRGHEVTVLASSA
SILFDPNNSSALKIEIYPTSLTKTELENFIMQQIKRWSDLPKDTFWLYFSQVQEIMSIFG
DITRKFCKDVVSNKKFMKKVQESRFDVIFADAIFPCSELLAELFNIPFVYSLSFSPGYTF
EKHSGGFIFPPSYVPVVMSELTDQMTFMERVKNMIYVLYFDFWFEIFDMKKWDQFYSEVL
GRPTTLSETMGKADVWLIRNSWNFQFPHPLLPNVDFVGGLHCKPAKPLPKEMEDFVQSSG
ENGVVVFSLGSMVSNMTEERANVIASALAQIPQKVLWRFDGNKPDTLGLNTRLYKWIPQN
DLLGHPKTRAFITHGGANGIYEAIYHGIPMVGIPLFADQPDNIAHMKARGAAVRVDFNTM
SSTDLLNALKRVINDPSYKENVMKLSRIQHDQPVKPLDRAVFWIEFVMRHKGAKHLRVAA
HDLTWFQYHSLDVIGFLLVCVATVIFIVTKCCLFCFWKFARKAKKGKND</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012558|UDP-glucuronosyltransferase 2B7 (UGT2B7)
ATGTCTGTGAAATGGACTTCAGTAATTTTGCTAATACAACTGAGCTTTTGCTTTAGCTCT
GGGAATTGTGGAAAGGTGCTGGTGTGGGCAGCAGAATACAGCCATTGGATGAATATAAAG
ACAATCCTGGATGAGCTTATTCAGAGAGGTCATGAGGTGACTGTACTGGCATCTTCAGCT
TCCATTCTTTTTGATCCCAACAACTCATCCGCTCTTAAAATTGAAATTTATCCCACATCT
TTAACTAAAACTGAGTTGGAGAATTTCATCATGCAACAGATTAAGAGATGGTCAGACCTT
CCAAAAGATACATTTTGGTTATATTTTTCACAAGTACAGGAAATCATGTCAATATTTGGT
GACATAACTAGAAAGTTCTGTAAAGATGTAGTTTCAAATAAGAAATTTATGAAAAAAGTA
CAAGAGTCAAGATTTGACGTCATTTTTGCAGATGCTATTTTTCCCTGTAGTGAGCTGCTG
GCTGAGCTATTTAACATACCCTTTGTGTACAGTCTCAGCTTCTCTCCTGGCTACACTTTT
GAAAAGCATAGTGGAGGATTTATTTTCCCTCCTTCCTACGTACCTGTTGTTATGTCAGAA
TTAACTGATCAAATGACTTTCATGGAGAGGGTAAAAAATATGATCTATGTGCTTTACTTT
GACTTTTGGTTCGAAATATTTGACATGAAGAAGTGGGATCAGTTTTATAGTGAAGTTCTA
GGAAGACCCACTACATTATCTGAGACAATGGGGAAAGCTGACGTATGGCTTATTCGAAAC
TCCTGGAATTTTCAGTTTCCATATCCACTCTTACCAAATGTTGATTTTGTTGGAGGACTC
CACTGCAAACCTGCCAAACCCCTGCCTAAGGAAATGGAAGACTTTGTACAGAGCTCTGGA
GAAAATGGTGTTGTGGTGTTTTCTCTGGGGTCAATGGTCAGTAACATGACAGAAGAAAGG
GCCAACGTAATTGCATCAGCCCTGGCCCAGATCCCACAAAAGGTTCTGTGGAGATTTGAT
GGGAATAAACCAGATACCTTAGGTCTCAATACTCGGCTCTACAAGTGGATACCCCAGAAT
GACCTTCTAGGTCATCCAAAGACCAGAGCTTTTATAACTCATGGTGGAGCCAATGGCATC
TACGAGGCAATCTACCATGGGATCCCTATGGTGGGGATTCCATTGTTTGCCGATCAACCT
GATAACATTGCTCACATGAAGGCCAGGGGAGCAGCTGTTAGAGTGGACTTCAACACAATG
TCGAGTACAGACTTGCTGAATGCATTGAAGAGAGTAATTAATGATCCTTCATATAAAGAG
AATGTTATGAAATTATCAAGAATTCAACATGATCAACCAGTGAAGCCCCTGGATCGAGCA
GTCTTCTGGATTGAATTTGTCATGCGCCACAAAGGAGCTAAACACCTTCGGGTTGCAGCC
CACGACCTCACCTGGTTCCAGTACCACTCTTTGGATGTGATTGGGTTCCTGCTGGTCTGT
GTGGCAACTGTGATATTTATCGTCACAAAATGTTGTCTGTTTTGTTTCTGGAAGTTTGCT
AGAAAAGCAAAGAAGGGAAAAAATGATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00201</identifier>
            <name>UDPGT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="7">
      <id>BE0004696</id>
      <name>UDP-glucuronosyltransferase 2B15</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17924</ref-id>
            <pubmed-id>20551237</pubmed-id>
            <citation>Ebner T, Wagner K, Wienen W: Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity. Drug Metab Dispos. 2010 Sep;38(9):1567-75. doi: 10.1124/dmd.110.033696. Epub 2010 Jun 15.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P54855" source="Swiss-Prot">
        <name>UDP-glucuronosyltransferase 2B15</name>
        <general-function>Glucuronosyltransferase activity</general-function>
        <specific-function>UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xenobiotic substrates, including simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones, and certain drugs and their hydroxylated metabolites. It also catalyzes the glucuronidation of endogenous estrogens and androgens.</specific-function>
        <gene-name>UGT2B15</gene-name>
        <locus/>
        <cellular-location>Microsome membrane</cellular-location>
        <transmembrane-regions>495-515</transmembrane-regions>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi/>
        <molecular-weight>61035.815</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12546</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P54855</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>UDB15_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.17</synonym>
          <synonym>HLUG4</synonym>
          <synonym>UDP-glucuronosyltransferase 2B8</synonym>
          <synonym>UDPGT 2B15</synonym>
          <synonym>UDPGT 2B8</synonym>
          <synonym>UDPGTh-3</synonym>
          <synonym>UGT2B8</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017513|UDP-glucuronosyltransferase 2B15
MSLKWTSVFLLIQLSCYFSSGSCGKVLVWPTEYSHWINMKTILEELVQRGHEVTVLTSSA
STLVNASKSSAIKLEVYPTSLTKNYLEDSLLKILDRWIYGVSKNTFWSYFSQLQELCWEY
YDYSNKLCKDAVLNKKLMMKLQESKFDVILADALNPCGELLAELFNIPFLYSLRFSVGYT
FEKNGGGFLFPPSYVPVVMSELSDQMIFMERIKNMIHMLYFDFWFQIYDLKKWDQFYSEV
LGRPTTLFETMGKAEMWLIRTYWDFEFPRPFLPNVDFVGGLHCKPAKPLPKEMEEFVQSS
GENGIVVFSLGSMISNMSEESANMIASALAQIPQKVLWRFDGKKPNTLGSNTRLYKWLPQ
NDLLGHPKTKAFITHGGTNGIYEAIYHGIPMVGIPLFADQHDNIAHMKAKGAALSVDIRT
MSSRDLLNALKSVINDPVYKENVMKLSRIHHDQPMKPLDRAVFWIEFVMRHKGAKHLRVA
AHNLTWIQYHSLDVIAFLLACVATVIFIITKFCLFCFRKLAKKGKKKKRD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017514|UDP-glucuronosyltransferase 2B15 (UGT2B15)
ATGTCTCTGAAATGGACGTCAGTCTTTCTGCTGATACAGCTCAGTTGTTACTTTAGCTCT
GGAAGCTGTGGAAAGGTGCTAGTGTGGCCCACAGAATACAGCCATTGGATAAATATGAAG
ACAATCCTGGAAGAGCTTGTTCAGAGGGGTCATGAGGTGACTGTGTTGACATCTTCGGCT
TCTACTCTTGTCAATGCCAGTAAATCATCTGCTATTAAATTAGAAGTTTATCCTACATCT
TTAACTAAAAATTATTTGGAAGATTCTCTTCTGAAAATTCTCGATAGATGGATATATGGT
GTTTCAAAAAATACATTTTGGTCATATTTTTCACAATTACAAGAATTGTGTTGGGAATAT
TATGACTACAGTAACAAGCTCTGTAAAGATGCAGTTTTGAATAAGAAACTTATGATGAAA
CTACAAGAGTCAAAGTTTGATGTCATTCTGGCAGATGCCCTTAATCCCTGTGGTGAGCTA
CTGGCTGAACTATTTAACATACCCTTTCTGTACAGTCTTCGATTCTCTGTTGGCTACACA
TTTGAGAAGAATGGTGGAGGATTTCTGTTCCCTCCTTCCTATGTACCTGTTGTTATGTCA
GAATTAAGTGATCAAATGATTTTCATGGAGAGGATAAAAAATATGATACATATGCTTTAT
TTTGACTTTTGGTTTCAAATTTATGATCTGAAGAAGTGGGACCAGTTTTATAGTGAAGTT
CTAGGAAGACCCACTACATTATTTGAGACAATGGGGAAAGCTGAAATGTGGCTCATTCGA
ACCTATTGGGATTTTGAATTTCCTCGCCCATTCTTACCAAATGTTGATTTTGTTGGAGGA
CTTCACTGTAAACCAGCCAAACCCCTGCCTAAGGAAATGGAAGAGTTTGTGCAGAGCTCT
GGAGAAAATGGTATTGTGGTGTTTTCTCTGGGGTCGATGATCAGTAACATGTCAGAAGAA
AGTGCCAACATGATTGCATCAGCCCTTGCCCAGATCCCACAAAAGGTTCTATGGAGATTT
GATGGCAAGAAGCCAAATACTTTAGGTTCCAATACTCGACTGTACAAGTGGTTACCCCAG
AATGACCTTCTTGGTCATCCCAAAACCAAAGCTTTTATAACTCATGGTGGAACCAATGGC
ATCTATGAGGCGATCTACCATGGGATCCCTATGGTGGGCATTCCCTTGTTTGCGGATCAA
CATGATAACATTGCTCACATGAAAGCCAAGGGAGCAGCCCTCAGTGTGGACATCAGGACC
ATGTCAAGTAGAGATTTGCTCAATGCATTGAAGTCAGTCATTAATGACCCTGTCTATAAA
GAGAATGTCATGAAATTATCAAGAATTCATCATGACCAACCAATGAAGCCCCTGGATCGA
GCAGTCTTCTGGATTGAGTTTGTCATGCGCCACAAAGGAGCCAAGCACCTTCGAGTCGCA
GCTCACAACCTCACCTGGATCCAGTACCACTCTTTGGATGTGATAGCATTCCTGCTGGCC
TGCGTGGCAACTGTGATATTTATCATCACAAAATTTTGCCTGTTTTGTTTCCGAAAGCTT
GCCAAAAAAGGAAAGAAGAAGAAAAGAGATTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00201</identifier>
            <name>UDPGT</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glucuronosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>flavonoid glucuronidation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="8">
      <id>BE0000220</id>
      <name>Ribosyldihydronicotinamide dehydrogenase [quinone]</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17925</ref-id>
            <pubmed-id>22494098</pubmed-id>
            <citation>Michaelis S, Marais A, Schrey AK, Graebner OY, Schaudt C, Sefkow M, Kroll F, Dreger M, Glinski M, Koester H, Metternich R, Fischer JJ: Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2). J Med Chem. 2012 Apr 26;55(8):3934-44. doi: 10.1021/jm3001339. Epub 2012 Apr 17.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16083" source="Swiss-Prot">
        <name>Ribosyldihydronicotinamide dehydrogenase [quinone]</name>
        <general-function>Nadph dehydrogenase (quinone) activity</general-function>
        <specific-function>The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis.</specific-function>
        <gene-name>NQO2</gene-name>
        <locus>6pter-q12</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.24</theoretical-pi>
        <molecular-weight>25918.4</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7856</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NQO2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J02888</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>190818</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16083</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NQO2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.10.5.1</synonym>
          <synonym>NMOR2</synonym>
          <synonym>NRH dehydrogenase [quinone] 2</synonym>
          <synonym>NRH:quinone oxidoreductase 2</synonym>
          <synonym>QR2</synonym>
          <synonym>Quinone reductase 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010014|Ribosyldihydronicotinamide dehydrogenase [quinone]
MAGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNLEPRATDKDITGTL
SNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRV
LCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFC
GFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010015|Ribosyldihydronicotinamide dehydrogenase [quinone] (NQO2)
ATGGCAGGTAAGAAAGTACTCATTGTCTATGCACACCAGGAACCCAAGTCTTTCAACGGA
TCCTTGAAGAATGTGGCTGTAGATGAACTGAGCAGGCAGGGCTGCACCGTCACAGTGTCT
GATTTGTATGCCATGAACCTTGAGCCGAGGGCCACAGACAAAGATATCACTGGTACTCTT
TCTAATCCTGAGGTTTTCAATTATGGAGTGGAAACCCACGAAGCCTACAAGCAAAGGTCT
CTGGCTAGCGACATCACTGATGAGCAGAAAAAGGTTCGGGAGGCTGACCTAGTGATATTT
CAGTTCCCGCTGTACTGGTTCAGCGTGCCAGCCATCCTGAAGGGCTGGATGGATAGGGTG
CTGTGCCAGGGCTTTGCCTTTGACATCCCAGGATTCTACGATTCCGGTTTGCTCCAGGGT
AAACTAGCGCTCCTTTCCGTAACCACGGGAGGCACGGCCGAGATGTACACGAAGACAGGA
GTCAATGGAGATTCTCGATACTTCCTGTGGCCACTCCAGCATGGCACATTACACTTCTGT
GGATTTAAAGTCCTTGCCCCTCAGATCAGCTTTGCTCCTGAAATTGCATCCGAAGAAGAA
AGAAAGGGGATGGTGGCTGCGTGGTCCCAGAGGCTGCAGACCATCTGGAAGGAAGAGCCC
ATCCCCTGCACAGCCCACTGGCACTTCGGGCAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02525</identifier>
            <name>Flavodoxin_2</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NADPH dehydrogenase (quinone) activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="2">
      <id>BE0001032</id>
      <name>P-glycoprotein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17305</ref-id>
            <pubmed-id>21327511</pubmed-id>
            <citation>Galanis T, Thomson L, Palladino M, Merli GJ: New oral anticoagulants. J Thromb Thrombolysis. 2011 Apr;31(3):310-20. doi: 10.1007/s11239-011-0559-8.</citation>
          </article>
          <article>
            <ref-id>A6979</ref-id>
            <pubmed-id>23292752</pubmed-id>
            <citation>Scaglione F: New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013 Feb;52(2):69-82. doi: 10.1007/s40262-012-0030-9.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08183" source="Swiss-Prot">
        <name>Multidrug resistance protein 1</name>
        <general-function>Xenobiotic-transporting atpase activity</general-function>
        <specific-function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.</specific-function>
        <gene-name>ABCB1</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>45-67
117-137
187-208
216-236
293-316
331-352
712-732
757-777
833-853
855-874
935-957
974-995</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.44</theoretical-pi>
        <molecular-weight>141477.255</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:40</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ABCB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M14758</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307180</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>MDR1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.6.3.44</synonym>
          <synonym>ATP-binding cassette sub-family B member 1</synonym>
          <synonym>MDR1</synonym>
          <synonym>P-glycoprotein 1</synonym>
          <synonym>PGY1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037114|Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016291|Multidrug resistance protein 1 (ABCB1)
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00005</identifier>
            <name>ABC_tran</name>
          </pfam>
          <pfam>
            <identifier>PF00664</identifier>
            <name>ABC_membrane</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity, coupled to transmembrane movement of substances</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>xenobiotic-transporting ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G2/M transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stem cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>